Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity

ABSTRACT

Hybrid compounds containing an aminotetralin moiety or a heterocyclic and/or open chain analog thereof linked through an alkylene group to an aryl ring system-substituted piperidiene moiety exhibit high levels of CNS activity, in some cases exhibiting especially high relative binding efficiencies between D3 and D2 dopaminergic receptor subtypes.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No. 10/344,285, filed Feb. 6, 2003, which is a continuation of International Application No. PCT/US02/18267, filed Jun. 7, 2002, which, in turn, claims the benefit of U.S. provisional application Ser. No. 60/296,622, filed Jun. 7, 2001.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention is directed to central nervous system pharmaceutically active compounds having both aryl-substituted piperazine and aminotetralin moieties, 5 or 7 membered cycloaliphatic ring homologues thereof, or open chain analogues thereof; and to their pharmacological use. These hybrid compounds exhibit high activity at various dopamine and serotonin receptor subtypes. Certain of the compounds exhibit high differential selectivity between D2 and D3 receptor subtypes.

2. Background Art

The dopamine receptors of the brain have proven fertile targets for pharmacological treatment of numerous central nervous system (“CNS”) disorders, including psychotic disorders such as schizophrenia and neurodegenerative disorders such as Parkinson's disease.⁸

In the last decade and a half, advances have been made in development of drugs specific for dopamine receptor subtypes, and in the development of novel pharmaceutically active compounds for their characterization.¹⁻³ In addition, in 1990, a new dopamine subtype receptor now known as the D3 receptor was discovered and subsequently cloned from rat complimentary DNA libraries using probes derived from the D2 receptor subtype.^(4,5) This new D3 receptor subtype belongs to the short form of D2 receptor subtype, and bears close resemblance to the latter.^(5,6,7)

Therapies involving D2-specific drugs often are associated with side effects like EPS, Tardive dyskinesia, believed to originate from blockage of D2 receptors in the striatal region of the brain.⁹ Studies probing the location of D3 receptors have shown that the distribution of the latter is different from the distribution of D2 receptors. In situ hybridization studies showed a lack of adequate presence in the caudate putamen area of the striatal section, and a dominant presence in the nucleus accumbens area.¹⁰ These different distribution patterns render the D3 receptors unique targets for drug development. D3-specific antagonists and agonists are expected to have numerous applications in treatment of psychotic disorders and neurodegenerative diseases without the undesirable side effects associated with pharmacology of the D2 receptor.^(1,12,13) Recent studies have shown that D3 specific compounds may also have therapeutic use in treatment of cocaine⁸ addiction.^(14,15,16) Efforts have thus been made to develop D3 specific drug candidates.

For example, 2-aminotetralins have been regarded as potent and selective agonists for D2 receptors.¹⁷⁻²⁰ However, 7-OH-DPAT and PD 128907, both aminotetralins, have shown preferential activity at the D3 receptor.²¹ Several other aminotetralin-related derivatives were also found to have such preferential selectivity.²² Aryl piperazines have also been demonstrated to have activity toward the D2 and D3 receptors,^(23,24) and some of these were found to have both high affinity and selectivity for the D3 receptor.²⁶ One such compound is GR103691,²⁵ containing a N-(methoxyphenyl)piperidine moiety linked to a 4′-acetyldiphenyl moiety through an N-alkyl-N-urethane linking group. A series of 8-hydroxy-2-aminotetralins bearing benzamide moieties have also been shown to have selective affinity for the D3 receptor,²⁷⁻²⁸ and a thiaza heterocyclic analog was shown to have high affinity and selectivity for this receptor subtype.²⁸

It would be desirable to provide additional pharmaceutically active compounds which exhibit high levels of CNS activity, for example, with respect to the dopaminergic receptors as well as the serotoninergic receptors. It would be further desirable to provide drug candidates which exhibit high activity with respect to the D3 receptor subtype, and in particular to provide drug candidates which exhibit high selectivity between the D2 and D3 subtypes.

SUMMARY OF THE INVENTION

It has now been surprisingly discovered that hybrid compounds containing both aminotetralin moieties, homologous 5 or 7 membered cycloaliphatic ring moieties, or their heterocyclic and/or open chain analogues, in conjunction with an aryl-substituted piperazinyl moiety, exhibit high CNS activity, in particular high D3 affinity and/or D3/D2 selectivity.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The subject invention compounds are hybrid compounds containing both an aminotetralin moiety or related structure as hereafter defined, and an N′-aryl piperazinyl structure, linked to the “aminotetralin” structure by an alkylene bridge.

Each of the subject invention compounds thus contains a 1,4-piperidinyl ring structure, bonded at one nitrogen thereof to an organic group containing an aryl group, including heteroaryl groups where the heteroatoms are N, O, S, or Se, and bonded at the other piperidinyl nitrogen via an intervening alkylene group to nitrogen of an aminotetralin or analog thereof. The intervening alkylene group may be part of a further ring structure containing the nitrogen of the aminotetralin. The aryl portion of the aminotetralin may constitute a substituted or unsubstituted aryl ring such as a fused phenyl moiety, or may be an analog, for example one containing a fused napthyl or higher aromatic moiety, or a 5 or 6 membered heteroaryl structure containing up to three heteroatoms individually selected from N, O, S, and Se.

Preferred embodiments include those of the general structure

wherein A is a C₆₋₁₀ aryl group, optionally substituted by an R² group comprising organyl groups preferably C₁₋₁₀ hydrocarbon groups optionally containing one or more O, N, S, or Se heteroatoms, more preferably selected from among C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl; C₆₋₁₀ aryl, —NR⁴ _(q) where R⁴ individually are H or organyl groups, preferably H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl, C₆₋₁₀ aryl and q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge; —NH—C(O)—R⁴, —NH—C(O)—NR⁴ ₂, and related compounds wherein the hydrocarbon groups in each case may optionally by substituted with —CN, C₁₋₄ lower alkyl, —OR⁴, —OH, halo, particularly fluoro and/or chloro, —CF₃, and the like. Two R² may also together form an alicyclic or aromatic fused five or six membered ring, optionally containing heteroatoms O, N, S, or Se, or containing a heteroaryl group substituted onto or fused with the aryl ring. The heteroatoms of the heteroaryl groups may be individually selected from O, N, S, and Se. Examples of preferred A groups include, without limitation, the following:

where Z is a heteroatom or a CH or CH₂ group, at least one Z being a heteroatom. The aryl ring may contain no R² substituents, or a plurality, preferably not more than two R² substituents.

In the above general structure, B is an aminotetralin residue or analog thereof. For example, the aminotetralin residue may be the aminotetralin moiety itself, optionally substituted, and linked via an alkylene bridge to the piperidinyl nitrogen, such as:

wherein R¹ is an organo group, preferably selected from among C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl, C₆₋₁₀ aryl, each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, etc. groups optionally halo substituted, preferably fluoro and/or chloro substituted, or substituted by —CN, C₁₋₄ lower alkoxy, C₁₋₄ acyloxy, C₁₋₄ acyl, —C(O)—R⁴, or —R⁵—NH—SO₂—NR⁴ _(r), and p is an integer, preferably 1 to 4, R¹ preferably being n-propyl and p preferably being 2. However, the aminotetralin nitrogen may also be part of a ring structure, optionally fused to the cycloaliphatic ring of the aminotetralin moiety, for example one of the structures

In the left most of these two structures, the (CH₂)_(p) alkylene linking group is part of the ring structure per se. In each of these moieties, the tetralin moiety may have fused aryl or heteroaryl rings, or be substituted by one or more R² substituents. Also, in the left-most structure, the bond to the piperidinyl nitrogen is shown at the 3-position relative to nitrogen, but can also be at the 1- or 4-positions.

Examples of structures corresponding to the above-described embodiments include the following:

wherein R¹ is an organo group, preferably selected from among C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl, C₆₋₁₀ aryl, each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, etc. groups optionally halo substituted, preferably fluoro and/or chloro substituted, or substituted by —CN, C₁₋₄ lower alkoxy, C₁₋₄ acyloxy, C₁₋₄ acyl, —C(O)—R⁴, or —R⁵—NH—SO₂—NR⁴ _(r), and p is an integer, preferably 1 to 4.

In one embodiment, the subject compounds have the following structure

is an aromatic and optionally heterocyclic ring system containing 5 or 6 ring atoms and up to three heteroatoms individually selected from the group consisting of N, O, S, and Se, this aromatic ring system optionally substituted by o R² groups, where o is 0, 1, 2, 3, or 4, the upper limit bounded by the number of available substituent sites. The R² groups are organyl groups preferably C₁₋₁₀ hydrocarbon groups optionally containing one or more O, N, S, or Se heteroatoms, more preferably selected from among C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl; C₆₋₁₀ aryl, —NR⁴ _(q) where R⁴ individually are H or organyl groups, preferably H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl, C₆₋₁₀ aryl and q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge; —NH—C(O)—R⁴, —NH—C(O)—NR⁴ ₂, and related compounds wherein the hydrocarbon groups in each case may optionally by substituted with —CN, C₁₋₄ lower alkyl, —OR⁴, —OH, halo, particularly fluoro and/or chloro, —CF₃, and the like. Two R² may also together form an alicyclic or aromatic fused five or six membered ring, optionally containing heteroatoms O, N, S, or Se.

R⁴ may also be arylsulfonyl, preferably 4-chlorophenylsulfonyl, 3,4-dichlorophenylsulfonyl; 4-(trifluoromethyl)phenylsulfonyl; R⁶—Ar—SO₂ where R⁶ is an electron withdrawing or electron donating substituent and Ar is an aromatic or heteroaromatic moiety; or keto, preferably phenylketo, 4-(trifluoromethyl)phenylketo, or aceto. Two R² may form part of a fused cycloalkyl or aryl ring, optionally containing N, O, S, or Se heterocycles. For example, two R² may combine to form the structures

R is H, C₁₋₄ lower alkyl, C₁₋₄ lower alkoxy, —CN, or is a methylene bonded to (CH)_(m), forming a 5 to 7 membered ring structure. In open chain analogues, m is 0 and R is not a methylene group bonded to (CH)_(m).

The compound contains n(CH)₂ groups, n being such that when m=0, n will be 0, 1 or 2 and R will be a methylene group linking the aromatic 5 to 7 membered ring with the CH group to form a cycloaliphatic ring structure which will contain 5 to 7 carbon atoms, or n is such that when the compound is an open chain analog, n may range from 0 to 4. Thus, when m=1 and n=1, the leftmost moiety in the formula will be an aminotetralin or heteroaryl analogue thereof.

R¹ is an organo group, preferably selected from among C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl, C₆₋₁₀ aryl, each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, etc. groups optionally halo substituted, preferably fluoro and/or chloro substituted, or substituted by —CN, C₁₋₄ lower alkoxy, C₁₋₄ acyloxy, C₁₋₄ acyl, —C(O)—R⁴, or —R⁵—NH—SO₂—NR⁴ _(r), where R⁵ is C₁₋₈ alkylene and r is 2 or 3, with the proviso that when r is 3, the nitrogen of the NR⁴ _(r) group will bear a positive formal charge; —R⁵—NH—C(O)—R⁴; —R⁵—NR⁴ _(r), —R⁵—Ar where Ar is an aryl ring system, preferably a C₆₋₁₀ aryl ring system, optionally including one or more heteroatoms, preferably phenyl, thienyl, pyridyl, biphenyl, or naphthyl.

The nitrogen of the aminotetralin or its heterocyclic and/or open chain analog is bonded to a nitrogen of the piperazinyl group through the intermediacy of p(CH₂) groups, where p is 1 to 4, preferably 2 to 4.

A is an aryl group optionally containing one or more heteroatoms bonded to the remaining nitrogen of the piperazinyl group. The aryl group may consist of from 1 to 4 rings, optionally fused, and optionally substituted by C₁₋₄ alkyl, C₂₋₄ alkenyl, C₅₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, halo, preferably fluoro or chloro, C₁₋₄ aldehyde, —NR⁴ _(q) and like groups. It should be noted that unsaturated groups such as alkenyl and cycloalkenyl include multiply unsaturated groups such as alkadienyl and cycloalkadienyl. Alkyl and cycloalkyl groups herein also include aryl-substituted alkyl and cycloalkyl groups, while aryl groups also include alkyl and cycloalkyl-substituted aryl groups. A is preferably optionally substituted thienyl, pyridinyl, phenyl, biphenyl, or naphthyl, more preferably phenyl and biphenyl. All the substituent classes of R, R¹, R², and R⁴ may be used as substituents on optionally substituted A. Preferred substituents include C₁₋₄ alkyl, —CN, halo, C₁₋₄ lower alkoxyl, and NH₂SO₂R⁴, CF₃, arylsulfonyl, arylsulfonamide, etc., more preferably o-OCH₃, 2,3-dichloro, and p-NHSO₂CH₃.

Preferred hybrid compounds include those having the structure I and II below:

where I represents an aminotetralin or heterocyclic analog thereof, while II represents an open chain, optionally heterocyclic analog thereof, i.e. a compound similar in overall structure to I but where the saturated aminotetralin ring is an open chain rather than cyclic moiety. In these and the foregoing formulae, X and Y are moieties which complete a 5 or 6 membered aromatic ring system. For example, X together with Y may be (CH)₄, forming a phenyl ring, or may be N—CH—S forming an thiazole ring. It is preferably that the X,Y-containing ring be a phenyl, aminothiazolyl, or aminopyridyl ring system. Preferred “closed ring” aminotetralin moiety compounds thus include II, III, and IV below:

In addition, the saturated aminotetralin ring or its 5 to 7 membered homologue in such ring systems may also include O or S heteroatoms, i.e. structure V below:

Preferred open chain analogues have the structure VI:

Additional preferred open chain structures include

Typical dosages for mammalian species may vary from 0.001 mg/Kg of body weight to about 100 mg/Kg of body weight, preferably 0.01 mg/Kg to 5 mg/Kg. The actual amount will vary depending upon the particular CNS activity desired to be altered, and the desired degree of alteration. The upper limits may, as with virtually all drugs, be limited by toxicity of the drug or its metabolites, or by the presence of unwanted side effects. The drugs may be administered in any form, but preferably in the form of tablets or capsules with appropriate excipients. Dosages, forms of administration, etc., can be readily determined by those skilled in the art.

Guidelines to the effective dosages in mammalian species are provided by the many known drugs commercially available which bind to CNS monoamine receptor sites, and by comparing the binding affinities of these pharmaceuticals with the target compounds of the subject invention by in vivo and in vitro studies. In addition to the utility of the subject invention compounds in treatment of diseases such as Parkinson's disease, schizophrenia, treatment for addiction such as cocaine addiction, and the like, the subject invention compounds are also useful, particularly in their radio labeled form, for clinical studies directed to distribution of monoamine receptor sites in the brain and the effect which compounds such as cocaine have on these sites.

All the compounds described above can be synthesized by techniques well known to those skilled in organic synthesis. Among the compounds synthesized are those included in Tables 1, 2, and 3 below. Table 1 includes aminotetralin hybrids per se, while Table 2 includes heterocyclic analogs thereof. In both Table 1 and Table 3, the leftmost aromatic ring is a phenyl ring, i.e., as shown in structures II and VI, respectively. Table 3 includes “open chain” analogues. In the tables, the substituent headings are those the corresponding to structural formulae II (Table 1); I (Table 2); and VI (Table 3). In Table 2, the “Ring” column specifies the heterocyclic ring portion which includes X and Y of structure I. The compounds identified in the tables represent compounds tested for CNS activity, the results of which are presented in Tables 4-8. However, additional compounds have been synthesized as well, as reported herein.

The compounds may be used per se or as pharmaceutically acceptable derivatives. The latter term includes salts, esters, and other derivatives generally considered acceptable by pharmaceutical standards. Useful derivatives, for example, include salts of organic and inorganic acids such as sulfates, phosphates, hydrohalide salts, carboxylate salts, etc., as well as esters of carboxylic acid or hydroxyl substituents, ethers of hydroxyl substituents, amides of amino substituents, as well as carbamates, ureas, etc. Synthesis of these derivatives is conventional, and well known to those skilled in pharmaceutical chemistry. For example, compounds bearing hydroxyl groups may be converted to esters by customary techniques of organic chemistry, such as reaction with an acyl halide, carboxylic acid anhydride, or by esterification with an acid while removing byproduct water. In some cases, derivation may be desired to facilitate compounding of the pharmaceutical into an acceptable form such as tablets, powder, aqueous dispersion, capsule, etc., or may be useful in assisting bioavailability of the drug following administration, for example by rendering the compound more or less soluble. In many cases, such as, for example, esters, ureas, carbamates, ethers, etc., the derivative may act as “prodrug,” which liberates the active form by biological transformation, i.e., by enzymatic hydrolysis of an ester functionality, as is well known to the pharmaceutical chemist. TABLE 1 Compound R² R¹ p A  8 7-OH 3-cyanopropyl 4 phenyl 10a 7-OH (4-benzoylamino)butyl 4 phenyl 10b 7-OH (2-benzoylamino)ethyl 4 phenyl 12a 7-OH propargyl 2 phenyl 12b 7-OH propargyl 4 phenyl 15a 7-OH propyl 2 phenyl 15b 7-OH propyl 4 phenyl 19a 7-OH propyl 4 2,3- dichlorophenyl 19b 7-OH propargyl 4 2,3- dichlorophenyl

TABLE 2 Compound* Ring R² R¹ A 23

2-NH₂ propyl phenyl 25

2-NH₂ propyl phenyl *p is 2 in each of the compounds of Table 2.

TABLE 3 Compound R² R¹ n* p A 29a 4-NH₂ propyl 1 2 phenyl 29b 3-NH₂ propyl 1 2 phenyl 30a 4-NHSO₂-φ-4Cl propyl 1 2 phenyl 30b 3-NHSO₂-φ-4Cl propyl 1 2 phenyl *m = 0 in all the open-chain compounds in Table 3.

CNS activity was assessed by in vitro testing on cloned human dopamine and serotonin receptors by standard techniques. These techniques are known by those skilled in the art to reflect in vivo activity. Techniques and their relationship to CNS activity are well known.²⁹⁻³⁵ Initial efforts resulted in the design and synthesis of novel compounds 12b and 15b. In designing of 10a-b it was decided to incorporate an additional benzamide moiety into the structural base to enhance the binding of these novel analogs by accessing the accessible domains in the receptor. It was conceived that such moieties might play a role in selectivity as well as activity.

These compounds were characterized for their binding at the cloned dopamine D₁, D₂, D₃ and D₄ receptor subtypes and also at the 5HT_(1A), 5HT_(2A) and 5HT_(2C) serotonin receptors subtypes (Tables 4 to 8). Compounds 15b and 12b with a 4-methylene long linker exhibited marked potency for the both D2 and D3 receptors and much weaker activity for the D1 receptor (Table 4). In addition, compounds 12b and 15b showed good affinity at the D4 receptor and were full agonists at this receptor. In the functional assay, compounds 15b and 12b showed preferential agonist activity at the D3 receptor while showing partial agonism at the D3 receptor (Table 7). On the other hand, compound 15a with a shorter, two-methylene chain linker, was more selective at the D3 receptor (Tables 1 and 5). The selectivity of 15a in this regard was more than two fold than the standard 7-OH-DPAT when assessed by the protocol used in Table 4 and was one of the most selective compounds in this series. The replacement of the phenyl group in 15b by a 2,3-dichlorophenyl moiety resulted in 19a which showed improved selectivity for the D3 receptor (15 vs. 1) compared to 15b. Replacement of the phenol moiety in compound 15a by a thiazolidinium moiety in 25 also resulted in much greater selectivity for the D3 receptor (Table 4; Table 8).

Amide-substituted piperazine derivatives 10a-b, were less active either at the dopamine or at the serotonin receptor subtypes while the cyano compound 8 showed modest activity at these receptors (Table 1 and 3).

Various compounds were tested against serotonin receptor subtypes. As shown in Table 6 these compounds were weak in their binding to the serotonin receptor subtypes except compounds 15a-b and 12a-b which showed good potency at the 5HT1A receptor.

Open chain analog compounds 30a-b were also synthesized and biologically characterized. SAR results indicate that compounds 30a-b with an electron withdrawing substituent are more potent than compounds not containing such a substituent (Table 5).

Biological Methods:

Biological studies were carried out with cloned human dopamine and serotonin receptors as described below.

D1 Receptor

LHD1 cells (human receptor) are grown and prepared as described for the HA7 cells as described hereafter. The final pellet is resuspended at 5 mg protein/80 ml in 50 mM Tris-HCl containing 120 mM of NaCl, 5 mM of KCl, 2 mM of CaCl₂, and 1 mM of MgCl₂, pH 7.4. To wells containing 100 μl of test drug or buffer and 100 ml of [³H]SCH 23390 (0.18 nM final conc.), is added 0.8 ml of cell homogenate (0.05 mg protein/well), and the plates are incubated at 250° C. for 60 min. Nonspecific binding is determined with 1 μM of SCH 23390.

D2 and D3 Receptors

CHOp-cells (human receptors) are grown to confluence in a minimum essential medium (α MEM) containing 10% fetal calf serum, 0.05% pen-strep, and 600 μg/ml of G418. The cells are scraped from the 100 by 20 mm plates and centrifuged at 500. g for 5 min. The pellet is homogenized by polytron in 50 mM Tris-HCl, pH 7.7, and centrifuged at 27,000-G for 12 min. The pellet is resuspended in 50 mM Tris, D₂ at 5 mg protein/ml, D₃ at 1 mg protein/ml, and stored at −70° C. in 1-ml aliquots.

On the day of the experiment, CHOp- D₂ or CHOp- D₃ cells are thawed, resuspended in 50 mM Tris, and centrifuged at 27,000-G for 12 min. The pellet is then resuspended at 5 mg protein/80 ml (D₂) and 1 mg protein/80 ml (D₃) in 50 mM Tris containing 120 mM of NaCl, 5 mM of KCl, 1.5 mM of CaCl₂, 4 mM of MgCl₂, and 1 mM of EDTA, pH 7.4. Then 0.8 ml of cell homogenate (0.05 and 0.01 mg protein/well, D₂ and D₃ respectively) is added to wells containing 100 μl of the test drug or buffer and 100/1 of [³H]YM-09151-2 (0.21 nM final conc.). Nonspecific binding is determined with 1 mM of chlorpromazine. The plates are incubated at 25° C. for 60 min before filtration and counted as usual. The filters are soaked in 0.1% PEI before filtering.

D4 Receptor

CHO D4.4 cells (human receptors) are grown to confluence in D₄ Puromycin medium containing 2 μg/ml puromycin, 5% fetal calf serum and 5% supplemented calf serum and 0.5% pen-strep. The cells are harvested as described for D₂ and D₃ cells and used at a concentration of 0.15 mg protein/well in the [³H]YM-09151-2 binding assay.

5-HT1A Receptor

HA7 cells (human receptor) are grown to confluence in DMEM containing 10% fetal calf serum, 0.05% penicillin-streptomycin (pen-strep), and 400 mg/ml of G418. The cells are scraped from the 100 by 20 mm plates and centrifuged at 500-G for 5 min. The pellet is homogenized in 50 mM Tris-HCl, pH 7.7, with a polytron, centrifuged at 27,000-G and resuspended at 10 mg protein/ml in the same buffer. The homogenate is then stored at −70° C. in 1-ml aliquots.

The thawed cells are washed once and resuspended at 10 mg protein/80 ml in 25 mM Tris-HCl containing 100 μM of ascorbic acid and 10 mM of nialamide at pH 7.4. The assay is performed in triplicate in a 96-well plate. To 100 μl of [³H]8-OH-DPAT (0.5 nM final conc), 100 ml of test compound or buffer and 0.8 ml of cell homogenate (0.1 mg protein/well) is added to each well by a Tomtec Quadra 96. Nonspecific binding is defined using 1 μM dihydroergotamine. The plates are incubated at 25° C. for 60 min, then filtered. The incubation is terminated by rapid filtration through glass fiber filter paper on a Tomtec cell harvester. The filters are washed four times with ice-cold 50 mM Tris-HCl, pH 7.7, dried overnight, bagged with 10 ml scintillation cocktail before counting for 2 min. on a Wallac Betaplate 1205 liquid scintillation counter.

Results of testing of several representative compounds for binding affinity at the D1, D2, D3 and D4 dopaminergenic receptor subtypes are presented in Table 4, along with 7-OH DPAT, known to have high affinity for the D3 receptor subtype and relatively high differential affinity between the D3 and D2 receptor subtypes. In interpreting the table, it should be noted that low values represent high affinity, i.e. high displacement of the reference binding ligand. Higher D2/D3 ratios thus represent higher relative affinity for the D3 receptor subtype as compared with the D2 receptor subtype. Preferred compounds have at least 1.5 times the D2/D3 ratio of 7-OH DPAT when measured by the same protocol. TABLE 4 Binding Affinity at the Cloned Human D1, D2, D3 and D4 Receptors Ki(nM), D1 Ki(nM), D2 Ki(nM), D3 Compound [³H]SCH23390 [³H]YM-09151-2 [³H]YM-09151-2 Ki(nM), D4 D2/D3 7-OH-DPAT  2548 ± 1082  16 ± 2.0 1.5 ± 0.4 10.6  8 3217.7 ± 7.77  89.79 ± 32.53 75.78 ± 6.29  142.26 ± 6.50  1.18 10a 3734.7 ± 272   119.16 ± 1.45  313.19 ± 6.47   136.9 ± 10.19 0.38 10b 2947.86 ± 237.81 110.94 ± 32.19  84.62 ± 1.55  35.63 ± 1.42 1.30 12a 662.6 65.5 23.48  2.8 12b 676.77 ± 34   6.54 ± 1.14 6.58 ± 1.15 28.93 ± 4.41 1 15a >10000 75.48 3.2  25 15b 6119.68 ± 932.83 3.37 ± 0.78 3.47 ± 0.08  25.66 ± 25.66 1 19a 4062.6  31.53 2.66 15 19b 1718.28 28.09 12.69  2.3

Table 4 indicates that all of the compounds tested had relatively high affinity for the D2, D3, and D4 receptor subtypes. Most had little affinity for the D1 receptor. Thus, all these compounds would be expected to exhibit CNS activity in vivo. Particularly noteworthy are compounds 15a and 19a, which exhibit considerably lower D1 receptor activity relative to 7-OH DPAT, and even higher activity differential as between the D2 and D3 receptors.

Various open chain analogues, those identified in Table 3, were also tested with respect to their binding affinities at the D2 and D3 receptors, as compared to 7-OH DPAT. The results are presented in Table 5. TABLE 5 Binding Affinity at the Cloned Human D2 and D3 Receptors Ki(nM), D2 Ki(nM), D3 Compound [³H]Spiperone [³H]Spiperone (+)-7-OH-DPAT  538 ± 108 5.00 ± 1.18 29a 25,553 ± 2,898 1,152 ± 130   29b 23,517 ± 2,097 1,478 ± 247   30a 702 ± 22 5.98 ± 0.70 30b 552 ± 31 36.8 ± 5.4 

Noteworthy is the exceptionally low affinity of compounds 29a and 29b for the D2 receptor, while showing some activity at the D3 receptor, and compound 30a, which exhibits differential binding affinity between the D2 and D3 receptors which is higher than that of 7-OH DPAT.

The compounds tested against dopaminergenic receptors and reported in Table 4 were also tested for binding affinity to the cloned human 5HT1A, 5HT2A, and 5HT2C serotonin receptors. A wide range of binding activity and differential binding activities considerably different from the activity exhibited by 7-OH DPAT is evident from the results presented in Table 6. TABLE 6 Binding Affinity at the Cloned Human 5HT1A, 5HT2A and 5HT2C Receptors Ki (nM), 5HT1A Ki (nM), 5HT2A Ki (nM), 5HT2C Compound [³H]8-OH-DPAT [³H]Ketanserin [³H]Mesulergine 7-OH-DPAT  193 ± 3.4 >10,000 >10,000  8 88.31 ± 0.40 700.77 ± 16.78 >10,000 10a 171.48 ± 32.17 1231.23 ± 217   >10,000 10b 163.98 ± 27.48 287.44 ± 50.24 >10,000 12a 27.64 160.6 2693.4  12b 15.25 ± 3.34 260.23 ± 41.94 3222.88 ± 52.90 15a 21.42 1541.59 >10,000 15b 18.47 ± 2.46 1784.26 ± 614.31 >10,000 19a 40.56 355.79 638.54 19b 64.38 160.22 264.28

Potential as domaminergenic agonists was assayed by ³H-thymidine incorporation by standard techniques. The results are presented in Table 7. TABLE 7 Evaluation of Agonist Potency by [³H]Thymidine Incorporation Experiment D2 % Maxm D3 % Maxm D4 % Maxm Compound EC50 (nM) Stim EC50 (nM) Stim EC50 (nM) Stim 7-OH-DPAT 4.2 ± 2.2 0.9 ± 0.6  8 74.49 ± 32.91 54.09 ± 4.82 68.11 ± 36.70 67.07 ± 1.93  54.76 ± 18.60 10a 115.28 ± 20.22  44.91 ± 0.84 110.23 ± 33.27  44.06 ± 11.55 32.21 ± 2.51  51.08 ± 1.72  10b 97.16 ± 47.74 27.03 ± 5.54 104.33 ± 57.28  50.93 ± 12.63 26.74 ± 10.55 71.36 ± 10.17 12a 6.18 ± 0.18 87.20 ± 2.16 1.25 ± 0.08 94.53 ± 6.17  12b 3.55 ± 1.34 85.01 ± 6.26 0.25 ± 0.03 71.69 ± 10.56 23.92 ± 3.57  85.15 ± 17.64 15a 1.59 ± 0.06 104.66 ± 11.33 0.97 ± 0.02 84.62 ± 10.75 15b 3.21 ± 0.46 120.72 ± 26.15 0.91 ± 0.46 74.92 ± 9.05  22.53 ± 10.98 102.81 ± 20.21  19a 8.31 ± 0.69 80.09 ± 8.15 6.49 ± 2.46 85.67 ± 1.19  19b 11.81 ± 1.84  85.66 ± 9.15 3.08 ± 1.09 90.34 ± 15.50

The mitogenesis study results presented in Table 7 assay the ability of these ligands to act as agonists or antagonists. The EC50 values thus indicate intrinsic activities or functional activities of these compounds. The value of % maximum stimulation indicates whether a compound is a partial agonist or full agonist. Generally, a value greater than 80% is considered as a full agonist and anything less than 80% is considered as a partial agonist. A compound will be considered antagonist if it produces a negative result (no [3H]thymidine incorporation) in the assay. All the compounds reported in Table 7 are either full agonists or partial agonists.

Inhibition constants for binding to cloned D2L and D3 receptors expressed in HEK cells by displacing [³H] spiperone were measured for several compounds. The results are presented in Table 8 below. TABLE 8 Inhibition Constants for Binding to the Closed D2L and D3 Receptors Expressed in HEK Cells by Displacing [³H]spiperone D2L HEK Cells D3 HEK Cells [³H]spiperone [³H]spiperone Compound Ki (nM) Ki (nM) D2L/D3 (+)-7-OH-DPAT  538 ± 108 5.00 ± 1.18 107.6  8  622 ± 102 50.2 ± 7.1  12.4 10a 782 ± 42 756 ± 48  1 10b 354 ± 2  55.7 ± 5.5  6.3 12a 245 ± 26 14.2 ± 1.7  17.2 12b 68.4 ± 7.6 1.40 ± 0.14 48.9 15a 213 ± 26 1.75 ± 0.34 121.7 15b 114 ± 8  3.79 ± 0.40 30 19a  8.78 ± 0.81 2.26 ± 0.50 3.8 19b  7.37 ± 0.27 3.59 ± 0.58 2.0 19c 27.4 ± 1.0 1.13 ± 0.04 24.2 23 1120 ± 144 22.3 ± 2.3  50 25 2080 ± 162 4.14 ± 0.55 502 Synthetic Procedures

A general synthetic scheme may be described as follows. Phenylpiperazine on N-alkylation with N-(4-bromoalkyl)phthalimide in presence of a base furnished 3a-b which on reaction with hydrazine released amine 4a-b. Reductive amination reaction of amine 4a-b with 7-methoxytetralone under standard conditions furnished amine 5a-b in good yield. N-Alkylation with bromocyanide resulted in cyano compounds 6a-b which were converted into amines 7a-b by reaction with lithium aluminum hydride (LAH). Demethylation of 6a with BBr₃ produced compound 8. Conversion of amines 7a-b to benzamide derivatives followed by demethylation produced compounds 10a-b. Similarly alkylation of 5a-b with propyl bromide produced N-alkylated derivatives which on demethylation produced final target compounds 12a-b. N-Acetylation of 5a-b followed by reduction with LAH furnished 14a-b. Demethylation of 14a-b produced final 15a-b. The dichloro compounds were synthesized in a similar manner.

Amine 4a was reacted with two isomeric nitrophenylacetic acid derivatives respectively to produce 26a-b which were converted to 28a-b by first reduction with BH₃ generated in situ by reaction of BF₃ with NaBH₄, followed by reaction with propionyl chloride to produce the intermediate amides. Final amine targets 29a-b were produced by reduction of the nitro group in compounds by catalytic hydrogenation followed by borane reduction The compounds 29a-b were converted into targets 30a-b by reacting with 4-chloro-phenylsulfonyl chloride. Amine 4a was reacted with 4-fluoropheneacetyl chloride to produce amide 26 which on reduction with lithium aluminum hydride followed by N-propylation produced the target 27. These reaction are presented in greater detail below.

Procedure A

N-[2-(4-Phenylpiperazin-1-yl)-ethyl]-phthalimide 3a

A mixture of 1-phenylpiperazine 2 (2.59 g, 15.98 mmol) was reacted with N-(2-bromoethyl)phthalimide (8.12 g, 31.96 mmol), Et₃N (2.0 mL) and K₂CO₃ (8.0 g) in DMF (40 mL) and stirred at 70° C. under N₂ overnight. After the reaction mixture was cooled down, water (100 mL) was added. The mixture was extracted with diethyl ether. The organic phase was combined and dried over Na₂SO₄. The solvent was removed under vacuo to give the crude product, which was purified by flash chromatography (Hexane/EtOac=1/1) to furnish 3a, 3.81 g (71%) ¹HNMR (CDCl₃) 2.68-2.72 (m, 6H, N(CH₂)₂, CONCH₂), 3.12-3.15 (t, J=4.8 Hz, 4H, N(CH₂)₂), 3.84-3.89 (t, J=6.3 Hz, 2H), 6.80-6.82 (t, J=8.1 Hz, 1H, Ar—H), 6.88-6.91 (d, J=8.1 Hz, 2H, Ar—H), 7.21-7.26 (t, J=8.1 Hz, 2H, Ar—H), 7.69-7.86 (m, 4H, Ar—H).

N-[4-(4-Phenylpiperazin-1-yl)-butyl]-phthalimide 3b

1-Phenylpiperazine 2 (2.21 g, 7.81 mmol) was reacted with N-(4-bromobutyl)phthalimide (1.26 g, 7.81 mmol) in the presence of K₂CO₃ (8.0 g) in Et₃N (1.0 mL) and DMF (20 mL) to give a yellow solid 3a, 2.70 (95%) (Procedure A). ¹H NMR (CDCl₃) 1.55-1.82 (m, 4H, CH₂CH₂), 2.40-2.45 (t, J=7.5 Hz, 2H, NCH₂), 2.57-2.61 (t, J=4.8 HZ, 4H, N(CH₂)₂), 3.17-3.20 (t, J=4.8 Hz, 4H, N(CH₂)₂), 3.71-3.75 (t, J=6.7 Hz, 2H, NCH₂), 6.82-6.94 (3H, Ar—H), 7.23-7.28 (m, 2H, Ar—H), 7.70-7.74 (m, 2H, Ar—H), 7.83-7.86 (m, 2H, Ar—H).

Procedure B

2-(4-Phenylpiperazin-1-yl)-ethylamine 4a

Into the solution of compound 3a (1.97 g, 5.88 mmol) in EtOH (25 mL) was added NH₂NH₂ (1.0 g, 31.2 mmol). The reaction mixture was stirred at room temperature under N₂ for 24 h. The solvent was removed under vacuo. EtOAc was added. The mixture was filtered and the solution was collected and dried over Na₂SO₄. The solvent was removed under vacuo to give a white solid 15, 1.18 g (98%) ¹HNMR (CDCl₃) 2.46-2.51 (t, J=6.3 Hz, 2H, CH₂NH₂), 2.68-2.71 (t, J=4.8 Hz, 4H, N(CH₂)₂), 2.86-2.92 (t, J=6.3 Hz, 2H, NCH₂), 3.12-3.16 (t, J=4.8 Hz, 4H, N(CH₂)₂), 6.81-6.83 (t, J=8.1 Hz, 1H, Ar—H), 6.88-6.91 (d, J=8.1 Hz, 2H, Ar—H), 7.21-7.26 (t, J=8.1 Hz, 2H, Ar—H).

4-(4-Phenylpiperazin-1-yl)-butylamine 4b

Compound 3b (7.70 g, 21.21 mmol) was reacted with NH₂NH₂ (3.0 g, 93.75 mmol) in EtOH (60 mL) to give 4b, 4.60 g (93%) (Procedure B). ¹H NMR (CDCl₃) 1.48-1.61 (m, 4H), 2.83-2.43 (t, J=7.2 Hz, 2H, NCH₂), 2.61-2.63 (t, J=4.5 Hz, 4H, N(CH₂)₂), 2.72-2.76 (t, J=6.4 Hz, 2H, NCH₂), 3.19-3.22 (t, J=4.6 Hz, 4H, N(CH₂)₂), 6.33-6.94 (m, 3H, Ar—H), 7.23-7.28 (m, 2H, Ar—H).

Procedure C

7-Methoxyl-2-[(N-(4-phenylpiperazin-1-yl)ethyl)-amino]tetralin 5a

A mixture of compound 4a (1.18 g, 5.75 mmol), 7-methoxyl-tetralone (1.22 g, 6.93 mmol) and Na(OAc)₃BH (3.60 g, 17.26 mmol) in ClCH₂CH₂Cl (20 mL) and HOAc (1.0 mL) was stirred at room temperature under N₂ overnight. After the solvent was evaporated, saturated NaHCO₃/H₂O (10 mL) was added and the mixture was extracted with EtOAc. The combined organic phase was dried over Na₂SO₄ and evaporated to give the crude product, which was purified by flash chromatography (EtOA/MeOH/Et₃N=50/5/1) to give solid 5a, 1.95 g (93%). ¹HNMR (CDCl₃) 1.60-1.68 (m, 2H), 2.60-2.63 (m, 6H, CH₂N(CH₂)₂), 2.76-3.04 (m, 7H), 3.16-3.20 (t, J=4.8 Hz, N(CH₂)₂), 3.77 (s, 3H, CH₃O), 6.62-6.71 (m, 2H, Ar—H), 6.64-7.02 (m, 4H, Ar—H), 7.24-7.30 (m, 2H, Ar—H).

7-Methoxyl-2-[(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 5b

4-(4-Aminobutyl)-1-phenylpiperazine 4 (4.30 g, 18.30 mmol) was reacted with 7-methoxyl-2-tetralone (3.21 g, 18.24 mmol) and Na(OAc)₃BH (11.40 g, 54.03 mmol) in 1,2-dichloroethane (50 mL) and HOAc (1.0 mL) to give a solid 5b 5.80 g (81%) (Procedure C). ¹H NMR (CDCl₃) 1.58-1.60 (m, 4H), 2.03-2.07 (m, 2H), 2.40-2.47 (t, J=6.7 Hz, 2H), 2.59-2.60 (t, J=4.8 Hz, m, 4H, N(CH₂)₂), 2.68-2.85 (m, 5H), 2.91-3.03 (m, 2H), 3.19-3.22 (t, J=4.8 Hz, 4H, N(CH₂)₂), 3.76 (s, 3H, CH₃O), 6.61-6.67 (m, 2H, Ar—H), 6.82-6.97 (m, 4H, Ar—H), 7.23-7.29 (m, 2H, Ar—H). Anal. C₂₅H₃₅N₃O Calcd: C, 76.29; H, 8.95; N, 10.68. Found: C, 76.08; H, 9.00; N, 10.57.

Procedure D

7-Methoxyl-2-[N-butyonitrile-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 6a

A mixture of 5b (1.38 g, 3.51 mmol), 4-bromobutyonitrile (1.39 g, 8.78 mmol), K₂CO₃ (5.0 g) and Et₃N (1.0 mL) was stirred in DMF (25 mL) at 60° C. under N₂ overnight. The mixture was diluted with water and extracted with diethyl ether. The combined organic phase was dried over Na₂SO₄ and evaporated to give crude product, which was purified by flash chromatography (EtOAc/Hexane/Et₃N=100/100/1) to give thick oil 6a 1.51 g (93%). ¹H NMR (CDCl₃) 1.47-1.62 (m, 7H), 1.77-1.81 (t, J=6.6 Hz, 2H, CH₂CN), 1.96-2.00 (m, 1H), 2.39-2.44 (t, J=7.2 Hz, 2H, NCH₂), 2.44-2.49 (t, J=7.0 Hz, NCH₂), 2.52-2.56 (t, 6.8 Hz, 2H, NCH₂), 2.61-2.64 (t, J=5.0 Hz, 4H, N(CH₂)₂), 2.73-2.93 (m, 5H), 3.21-3.24 (t, J=4.8 Hz, 4H, N(CH₂)₂), 3.77 (s, 3H, CH₃O), 6.63-6.71 (m, 2H, Ar—H), 6.84-7.01 (m, 4H, Ar—H), 7.25-7.30 (m, 2H, Ar—H).

7-Methoxyl-2-[N-acetonitrile-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 6b

A mixture of 5b (0.63 g, 1.60 mmol) was reacted with bromoacetonitrile (0.50 g, 4.17 mmol), K₂CO₃ (2.20 g) in Et₃N (1.0 mL) and DMF(25 mL) to give a thick oil 6b, 0.53 g (76%) (Procedure D). ¹H NMR (CDCl₃) 1.52-1.81 (m, 4H), 2.09-2.17 (m, 2H), 2.40-2.44 (t, J=6.3 Hz, 2H), 2.60-2.63 (t, J=4.6 Hz, 4H, N(CH₂)₂), 2.74-2.88 (m, 5H), 2.89-2.99 (m, 2H), 3.31-3.35 (t, J=4.8 Hz, 4H, N(CH₂)₂), 3.67 (s, 2H, CH₂CN), 3.77 (s, 3H, CH₃O), 6.61-6.71 (m, 2H, Ar—H), 6.85-6.97 (m, 4H, Ar—H), 7.24-7.29 (m, 2H, Ar—H).

Procedure E

7-Methoxyl-2-[N-(4-aminobutyl)-(N-(4-phenylpiperazin-1-yl)-butyl)amino]-tetralin 7a

Dry THF (5 mL) wad added dropwise into lithium aluminum hydride (LAH) (0.13 g, 3.68 mmol) in ice bath under N₂. Compound 6a (0.30 g, 0.65 mmol) in dry THF (15 mL) was added dropwise into above LAH/THF suspension. The reaction mixture was refluxed for 8 h. After the reaction mixture was cooled to room temperature, saturated NaOH/H₂O (1 mL) was added dropwise. The mixture was filtered and the solution was dried over Na₂SO₄. The solvent was removed under vacuo to give a white solid 7a, 0.30 g (97%). ¹H NMR (CDCl₃) 1.56-1.90 (m, 8H), 2.03-2.08 (m, 2H), 2.46-2.51 (t, J=7.2 Hz, 2H), 2.61-2.67 (m, 4H), 2.67-2.70 (t, J=4.8 Hz, 4H, N(CH₂)₂), 2.77-2.93 (m, 6H), 3.03-3.10 (m, 1H), 3.27-3.30 (t, J=4.8 Hz, 4H, N(CH₂)₂), 3.77 (s, 3H, CH₃O), 6.63-6.70 (m, 2H, Ar—H), 6.83-6.94 (m, 4H, Ar—H), 7.24-7.29(m, 2H, Ar—H).

7-Methoxyl-2-[N-(2-aminoethyl)-(N-(4-phenylpiperazin-1-yl)-butyl)amino]-tetralin 7b

Compound 6b (0.37 g, 0.86 mmol) was reacted with LAH (0.23 g, 7.60 mmol) in dry THF (20 mL) to give a white solid 7b, 0.35 g (95%) (Procedure E). ¹H NMR (CDCl₃) 1.54-1.65 (m, 4H), 2.09-2.13 (m, 2H), 2.39-2.44 (t, J=7.2 Hz, 2H), 2.59-2.63 (m, J=4.5 Hz, 4H, N(CH₂)₂), 2.74-2.89 (m, 10H), 3.02-3.06 (m, 1H), 3.19-3.22 (t, J=4.8 HZ, 4H, N(CH₂)₂), 3.77 (s, 3H, CH₃O), 6.63-6.71 (m, 2H, Ar—H), 6.83-6.92 (m, 4H, Ar—H), 7.25-7.30 (m, 2H, Ar—H).

Procedure F

7-Hydroxyl-2-[N-butyonitrile-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 8

Compound 6a (0.29 g, 0.63 mmol) was dissolved in dry CH₂Cl₂ (10 mL). The solution was cooled to −40° C. by dry ice. The solution of 1M BBr₃/CH₂Cl₂ (1.0 mL) was added slowly. The reaction mixture was stirred at −40° C. for 2 h and then at room temperature overnight. Saturated NaHCO₃/H₂O was added and the mixture was extracted by CH₂Cl₂. The combined organic phase was dried over Na₂SO₄. After the solvent was removed under vacuo, the crude product was purified with flash chromatography (EtOAc/Et₃N=5011) to give compound 8, 0.18 g (65%). ¹H NMR (CDCl₃) 1.47-1.61 (m, 8H), 1.75-1.79 (t, J=6.6 Hz, 2H, CH₂CN), 1.94-1.97 (m, 2H), 2.39-2.47 (m, 4H), 2.49-2.54 (t, J=6.3 Hz, 2H, NCH₂), 2.61-2.64 (t, J=5.1 Hz, 4H, N(CH₂)₂), 2.69-2.91 (m, 5H), 3.20-3.23 (t, J=4.5 Hz, 4H, N(CH₂)₂), 6.54-6.60 (m, 2H, Ar—H), 6.83-6.95 (m, 3H, Ar—H), 7.24-7.29 (m, 2H, Ar—H). Free base was converted into its HBr salt. m.p.=171-175° C. Anal. (C₂₈H₃₈N₄O 3HBr) Cacl: C, 49.94; H, 6.14; N, 8.32; Found: C, 49.94; H, 6.28; N, 8.29.

Procedure G

7-Methoxyl-2-[N-(4-benzoylaminobutyl)-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 9a

Benzoic acid (0.10 g, 0.78 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.14 g, 0.71 mmol) and 1-hydroxybenzotriazole (0.11 g, 0.78 mmol) were dissolved in dry CH₂Cl₂ (10 mL). The solution was stirred at room temperature for 0.5 h. 7a (0.30 g, 0.65 mmol) in CH₂Cl₂ (10 mL) was added into the above solution. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated and H₂O (50 mL) was added. The mixture was extracted with EtOAc. The organic phase was dried over Na₂SO₄. After evaporation, the crude product was purified with flash chromatography (EtOAc/Et₃N=50/1) to give compound 9, 0.26 g (71%). ¹H NMR (CDCl₃) 1.52-1.67 (m, 8H). 1.97-2.05 (m, 2H), 2.36-2.41 (t, J=6.9 Hz, 2H), 2.59-2.62 (t, J=4.8 Hz, 6H, N(CH₂)₂, NCH₂), 2.74-2.87 (m, 4H), 2.97-3.07 (m, 1H), 3.18-3.22 (t, J=4.8 Hz, N(CH₂)₂), 3.46-3.52 (t, J=6.2 Hz, 2H), 3.71(s, 3H, CH₃O), 6.57-6.71 (m, 2H), 6.84-7.00 (m, 4H, Ar—H), 7.25-7.27 (m, 2H, Ar—H), 7.40-7.52 (m, 3H, Ar—H), 7.77-7.79 (d, J=7.9 Hz, 2H).

7-Methoxyl-2-[N-(2-benzoylamino)ethyl-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 9b

Compound 7b (0.35 g, 0.84 mmol) was reacted with benzonic acid (0.12 g, 1.02 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide-hydrochloride (0.19 g, 0.10 mmol) and 1-hydroxybenzotriazole (0.14 g, 1.01 mmol) in CH₂Cl₂ (20 mL) to give compound 9b, 0.30 g (69%) (Procedue G). ¹H NMR(CDCl₃) 1.53-1.61 (m, 4H), 1.97-2.05 (m, 2H), 2.34-2.38 (t, J=6.2 Hz, 2H), 2.53-2.42 (t, J=4.2 Hz, 4H, N(CH₂)₂), 2.59-2.62 (m, 2H), 2.73-2.81 (m, 6H), 3.03-3.05 (m, 1H), 3.13-3.16 (t, J=4.5 Hz, 4H, N(CH₂)₂), 3.48-3.52 (m, 2H), 3.76(s, 3H, CH₃O), 6.59-6.68 (m, 2H, Ar—H), 6.85-7.00 (m, 4H, Ar—H), 7.24-7.28 (m, 2H, Ar—H), 7.42-7.51 (m, 3H, Ar—H), 7.78-7.80 (d, J=6.9 Hz, 2H, Ar—H).

7-Hydroxyl-2-[N-(4-benzoylaminobutyl)-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 10a

Compound 9a (0.17 g, 0.30 mmol) was reacted with 1.0 M BBr₃/CH₂Cl₂ (1.5 mL) to give compound 10a, 0.12 g (72%) (Procedure F). m.p.=70-71° C. ¹H NMR (CDCl₃) 1.52-1.69 (m, 8H), 1.97-2.05 (m, 2H), NCH₂), 2.54-2.61 (m, 6H, N(CH₂)₂), 2.71-2.84 (m, 4H), 2.36-2.41(t, J=6.9 Hz, 2H), 2.95-3.05(m, 1H, NCH), 3.18-3.21(t, J=4.6 Hz, 4H, N(CH₂)₂), 3.45-3.51 (t, J=6.2 Hz, 2H), 6.52-6.61(m, Ar—H, 2H), 6.83-6.88(m, 4H, Ar—H), 7.24-7.29 (m, 2H, Ar—H), 7.39-7.49 (m, 3H, Ar—H), 7.76-7.79(d, J=7.2 Hz, 2H, Ar—H) Anal. C₃₅H₄₆N₄O₂0.22H₂O, Cacl: C, 75.26; H, 8.37; N, 10.01; Found: C, 75.23; H, 8.28; N, 9.75.

7-Hydroxyl-2-[N-(2-benzoylamino)ethyl-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 10b

Compound 9b (0.28 g, 0.53 mmol) was reacted with 1M BBr₃/CH₂Cl₂ (2.0 mL, 2.0 mmol) to give compound 10b, 0.21 g(76%) (Procedure F). m.p.=68-69° C. ¹H NMR(CDCl₃) 1.54-1.70 (m, 4H), 1.89-2.05 (m, 2H), 2.35-2.39 (t, J=4.9 Hz, 2H), 2.53-2.56 (t, J=4.2 Hz, 4H, N(CH₂)₂), 2.61-2.67 (m, 2H), 2.72-2.98 (m, 6H), 2.99-3.07 (m, 2H), 3.14-3.17 (t, J=4.5 Hz, 4H, N(CH2)2), 3.45-3.53 (m, 2H), 6.51-6.61 (m, 2H, Ar—H), 6.86-6.92 (m, 4H, Ar—H), 7.24-7.29 (m, 2H, Ar—H), 7.42-7.51 (m, 3H, Ar—H), 7.79-7.81(d, J=6.9 Hz, 2H, Ar—H). Anal. (C₃₅H₄₈N₄O₂0.22H₂O) Cacl: C, 74.75; H, 8.05; N, 10.56; Found, C, 74.80; H, 8.22; N, 10.03.

7-Methoxyl-2-[N-propargyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]tetralin 11a

Compound 5a (1.18 g, 3.04 mmol) was reacted with propargyl chloride (1.20 g, 16.11 mmol) in the presence of K₂CO₃ (4.0 g) and DMF (25 mL) at 60° C. for 5 h to furnish 10a, 0.35 g (29%) (Procedure D). ¹HNMR (CDCl₃) 1.59-1.71 (m, 2H), 2.13-2.18 (m, 2H), 2.20-2.34 (t, J=2.1 Hz, 1H, C≡CH), 2.56-2.60 (t, J=6.9 Hz, 2H, NCH₂), 2.65-2.68 (t, J=4.8 Hz, 4H, N(CH₂)₂), 2.75-2.81 (m, 2H), 2.84-2.89 (t, J=7.2 Hz, 2H). 2.98-3.02 (m, 3H), 3.20-3.23 (t, J=4.8 Hz, 4H, N(CH₂)₂), 3.60 (s, 2H, NCH₂C≡CH), 3.77 (s, 3H, CH₃O), 6.60-6.83 (m, 2H, Ar—H), 6.85-6.98 (m, 4H, Ar—H), 7.23-7.29 (m, 2H, Ar—H).

7-Methoxyl-2-[N-propargyl-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 11b

A mixture of 5b (0.65 g, 1.65 mmol), propagyl chloride (0.30 mL, 4.63 mmol), K₂CO₃ (1.0 g) and Et₃N (1.0 mL) was stirred in DMF (20 mL) at 60° C. under N₂ for 5 h to give a thick oil 11b, 0.33 g (46%) (Procedure D). ¹H NMR (CDCl₃) 1.51-1.56 (m, 4H), 2.11-2.15 (m, 2H), 2.17-2.19 (t, J=2.2 HZ, 1H, C≡CH), 2.40-2.44 (t, J=7.2 Hz, 2H), 2.59-2.63 (t, J=4.8 Hz, 4H, N(CH₂)₂), 2.67-2.83 (m, 5H), 2.93-3.01 (m, 2H), 3.19-3.23 (t, J=4.5 HZ, 4H, N(CH₂)₂), 3.52-3.53 (d, J=2.1 Hz, 2H, H₂C≡CH), 3.77 (s, 3H, CH₃O), 6.62-6.70 (m, 2H, Ar—H), 6.83-7.00 (m, 4H, Ar—H), 7.24-7.29 (m, 2H, Ar—H).

7-Hydroxyl-2-[N-propargyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]tetralin 12a

Compound 11a (0.28 g, 0.70 mmol) was reacted with 1M BBr₃/CH₂Cl₂ (1.50 mL, 1.50 mmol) in CH₂Cl₂ (15 mL) to furnish 12a, 0.23 g (84%) (Procedure E). ¹HNMR (CDCl₃) 1.56-1.68 (m, 2H), 2.11-2.15 (m, 2H), 2.20-2.22 (t, J=2.1 Hz, 1H, C≡CH), 2.57-2.61 (t, J=6.6 Hz, 2H, NCH₂), 2.65-2.69 (t, J=4.8 Hz, 4H, N(CH₂)₂), 2.75-2.81 (m, 2H), 2.86-2.91 (t, J=4.8 Hz, 2H, N(CH₂)₂), 3.58 (s, 2H, CH₂C≡CH), 6.55-6.61 (m, 2H, Ar—H), 6.83-6.94 (m, 4H, Ar—H). 7.23-7.27 (m, 2H, Ar—H). Free base was converted into its HCl salt. m.p.=164-166° C. Anal. (C₂₇H₃₁N₃O₃HCl 0.8H₂O) Calcd. C, 58.49; H, 6.98; N, 8.18; Found: C, 58.58; H, 6.77; N, 8.05.

7-Hydroxyl-2-[N-propargyl-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 12b

Compound 11b (0.195 g, 0.742 mmol) was reacted with 1M BBr₃/CH₂Cl₂ (0.80 mL, 0.80 mmol) to give compound 12b, 0.13 g (72%). ¹HNMR (CDCl₃) 1.54-1.68 (m, 4H), 2.09-2.14 (m, 2H), 2.17-2.18 (t, J=2.1 Hz, 1H), 2.41-2.45 (t, J=7.0 Hz, 2H), 2.60-2.63 (t, J=4.5 Hz, 4H, N(CH₂)₂), 2.67-2.71 (t, J=6.2 Hz, 2H), 2.76-2.80 (m, 3H), 2.89-2.92 (m, 1H) 3.51-3.52 (d, J=2.1 Hz, 2H, CH₂C≡CH), 3.20-3.24 (t, J=4.6 Hz, 4H, N(CH₂)₂), 6.56-6.61 (m, 2H, Ar—H), 6.88-6.95 (m, 4H, Ar—H), 7.24-7.29 (m, 2H, Ar—H),). Free base was converted into its HBr salt. m.p.=182-186° C. Anal. (C₂₇H₃₅N₃O₃HBr0.75H₂O). Cacl: C, 48.12; H, 5.87; N, 6.24; Found: C, 48.12; H, 5.86; N, 6.20.

Procedure H

7-Methoxyl-2-[N-propionyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]tetralin 13a

Compound 5a (0.36 g, 0.97 mmol) was dissolved in CH₂Cl₂ (10 mL) and Et₃N (1.0 mL). The solution was cooled in an ice bath, and propionyl chloride (0.20 g, 2.16 mmol) was added. After the reaction mixture was stirred at room temperature for 2 h, TLC showed completion of the reaction. The solvent was removed under vacuo. The mixture was dissolved in EtOAc and washed with H₂O. The organic phase was dried over Na₂SO₄. The evaporation of the solution gave the crude product, which was purified by flash chromatography (EtOAc/MeOH/Et₃N=95/5/0.5) to give 13a, 0.42 g (93%) (Procedure F). ¹HNMR (CDCl₃) 1.14-1.20 (t, J=6.6 Hz, 3H, CH₃CH₂CO), 1.63-1.70 (m, 2H), 1.90-2.04 (m, 2H), 2.40-2.50 (m, 4H), 2.66-2.74 (t, J=4.8 Hz, 4H, N(CH₂)₂),2.76-2.91 (m, 5H), 3.20-3.22 (t, J=4.8 Hz, 4H, N(CH₂)₂), 3.78 (s, 3H, CH₃O), 6.60-6.70 (m, 2H, Ar—H), 6.91-7.01 (m, 4H, Ar—H), 7.25-7.29 (m, 2H, Ar—H).

7-Methoxyl-2-[N-propionyl-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 13b

Compound 5b (0.28 g, 0.71 mmol) was reacted with propionyl chloride (0.25 g, 3.57 mmol) in CH₂Cl₂ (10 mL) and Et₃N (1.0 mL) to give pure compound 18, 0.32 g (99%). ¹H NMR (CDCl₃) 1.11-1.26 (t, J=6.6 Hz, 3H), 1.52-1.74 (m, 5H), 1.89-1.98 (m, 1H), 2.35-2.45(m, 4H), 2.58-2.61 (t, J=4.5 Hz, 4H, N(CH₂)₂), 2.78-3.05 (m, 4H), 3.18-3.23 (t, J=4.5 Hz, 4H, N(CH₂)₂), 3.15-3.56 (m, 1H), 3.76 (s, 3H, CH₃O—), 6.58-6.73 (m, 2H, Ar—H), 6.85-7.03 (m, 4H, Ar—H), 7.23-7.28 (t, J=7.6 Hz, 2H, Ar—H).

7-Methoxyl-2-[N-propyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]tetralin 14a

Compound 13a (0.38 g, 0.90 mmol) was reacted with LAH (0.15 g, 4.41 mmol) in THF (25 mL) to furnish 14a, 0.36 g (97%) (procedure E). ¹HNMR (CDCl₃) 0.87-0.93 (t, J=7.2 Hz, 3H, CH₃CH₂CH₂N), 1.46-1.53 (m, 4H), 1.88-2.07 (m, 2H), 2.51-2.55 (t, J=7.2 Hz, 2H, CH₂N), 2.64-2.68 (t, J=4.8 Hz, 4H, N(CH₂)₂), 2.72-2.83 (m, 6H), 2.90-3.06 (m, 1H), 3.19-3.22 (t, J=4.8 Hz, 4H, N(CH₂)₂), 3.77 (s, 3H, CH₃O), 6.62-6.70 (m, 2H, Ar—H), 6.85-7.00 (m, 4H, Ar—H), 7.24-7.29 (m, 2H, Ar—H).

7-Methoxyl-2-[N-propyl-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 14b

Compound 13b (0.30 g, 0.71 mmol) was reacted with LAH (0.25 g, 7.57 mmol) in THF (20 mL) to give 14b 0.28 g (99%) (procedure E). ¹H NMR (CDCl₃) 0.86-0.91 (t, J=7.2 Hz, 3H), 1.40-1.66 (m, 7H), 1.98-2.05 (m, 1H), 2.38-2.43 (t, J=7.2 Hz, 2H), 2.45-2.50 (t, J=7.2 Hz, 2H), 2.52-2.56 (t, J=6.8 Hz, 2H), 2.59-2.62 (t, J=4.8 Hz, 4H, N(CH₂)₂), 2.69-2.88 (m, 4H), 2.91-3.02 (m, 1H), 3.20-3.22 (t, J=4.5 Hz, 4H, N(CH₂)₂), 3.77 (s, 3H, CH₃O), 6.62-6.69 (m, 2H, Ar—H), 6.83-7.00 (m, 4H, Ar—H), 7.24-7.29 (m, 2H, Ar—H).

7-Hydroxyl-2-[N-propyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]tetralin 15a

Compound 14a (0.60 g, 0.88 mmol) was reacted with 1M BBr₃/CH₂Cl₂ (1.60 mL, 1.60 mmol) in CH₂Cl₂ (20 mL) to furnish 15a, 0.29 g (83%) (Procedure F). ¹H NMR (CDCl₃) 0.86-0.91 (t, J=7.2 Hz, 3H, CH₃CH₂CH₂N), 1.43-1.50 (m, 4H), 1.89-1.93 (m, 2H), 2.46-2.51 (t, J=7.5 Hz, 2H, NCH₂), 2.53-2.68 (m, 6H), 2.70-2.74 (t, J=4.8 Hz, 4HN(CH₂)₂), 2.83-2.88 (m, 1H), 3.23-3.26 (t, J=4.8 Hz, 4H, N(CH₂)₂), 6.45-6.56 (m, 2H, Ar—H), 6.83-6.93 (m, 4H, Ar—H), 7.23-7.26 (m, 2H, Ar—H). Free base was converted into its HCl salt, m.p.=143-146° C. Anal. (C₂₇H₃₅N₃O.3HCl 0.9H₂O) Calcd. C, 57.83; H, 7.72; N, 8.09; Found: C, 57.88; H, 7.52; N, 7.90.

7-Hydroxyl-2-[N-propyl-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 15b

Compound 19 (0.30 g, 0.69 mmol) was reacted with 1M BBr₃/CH₂Cl₂ (1.3 mL) to give 20, 0.25 g (87%) (Procedure F). ¹H NMR (CDCl₃) 0.86-0.91 (t, J=7.2 Hz, 3H), 1.40-1.82 (m, 7H), 1.93-2.05 (m, 1H), 2.39-2.44 (t, J=7.2 Hz, 2H), 2.44-2.50 (t, J=7.5 Hz, 2H), 2.56-2.51(t, J=6.6 Hz, 2H), 2.60-2.63 (t, J=4.2 Hz, 4H, N(CH₂)₂), 2.75-2.80 (m, 4H), 2.92-2.99 (m, 1H), 3.20-3.23 (t, J=4.2 Hz, 4H, N(CH₂)₂), 6.54-6.60 (m, 2H, Ar—H), 6.83-6.95 (m, 4H, Ar—H), 7.24-7.29 (m, 2H, Ar—H). Free base was converted into its HBr salt. m.p.=152-156° C. Anal. C₂₇H₄₂N₃OBr₃.0.30H₂O. Cacl: C, 48.42; H, 6.41; N, 6.27. Found: C, 48.10; H, 6.64; N, 6.11.

7-Methoxyl-2-[(N-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butyl)amino]tetralin 17

Compound 17 was synthesized from 16 according to the procedures (A, B and C) (70%, 3 steps). ¹HNMR (CDCl₃) 1.58-1.64 (m, 4H), 2.04-2.10 (m, 2H), 2.43-2.47 (t, J=6.6 Hz, 2H), 2.60-2.65 (m, 4H(N(CH₂)₂), 2.76-2.82 (m, 5H), 2.93-2.98 (m, 2H), 3.02-3.08 (m, 4H, N(CH₂)₂), 3.77 (s, 3H, CH₃O), 6.62-6.71 (m, 2H, Ar—H), 6.94-7.01 (m, 2H, Ar—H), 7.14-7.16 (m, 2H, Ar—H).

7-Methoxyl-2-[N-propanyl-(N-(4-(23-dichlorophenyl)-piperazin-1-yl)-butyl)amino]tetralin 18a

Compound 18a was synthesized from 17 according to the procedure (H, E) in (92%, two steps). ¹HNMR (CDCl₃) 0.89-0.93 (t, J=7.2 Hz, 3H, CH₃CH₂), 1.47-1.61 (m, 6H), 2.02-2.05 (m, 2H), 2.44-2.49 (t, J=7.2 Hz, 2H, NCH₂), 2.52-2.65 (m, 8H), 2.76-2.87 (m, 5H), 3.07-3.08 (bs, 4H, N(CH₂)₂), 3.77 (s, 3H, CH₃O), 6.63-6.70 (m, 2H, Ar—H), 6.95-7.00 (m, 2H, Ar—H), 7.14-7.19 (t, J=2.7 Hz, 2H, Ar—H).

7-Methoxyl-2-[N-propargyl-(N-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butyl)amino]tetralin 18b

Compound 17 was reacted with propargyl chloride (1.50 g, 20.13 mmol) and K₂CO₃ (4.50 g) in DMF (20 mL) to give 18b, 0.48 g (24%). ¹HNMR (CDCl₃) 1.55-1.68 (m, 4H), 2.11-2.15 (m, 2H), 2.17-2.18.(t, J=1.8 Hz, 1H, C≡CH), 2.43-2.47 (t, J=6.6 Hz, 2H), 2.49-2.66 (bs, 4H, N(CH₂)₂), 2.68-2.88 (m, 8H), 2.98-3.00 (m, 1H), 3.06-3.10 (bs, 4H, N(CH₂)₂), 3.52-3.53 (d, J=1.8 Hz, 2H, CH2C≡CH), 3.77 (s, 3H, CH₃O), 6.30-6.72 (m, 2H, Ar—H), 6.94-7.00 (m, 2H, Ar—H), 6.97-7.16 (m, 2H, Ar—H).

7-Hydroxyl-2-[N-propyl-(N-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butyl)amino]tetralin 19a

Compound 10 (0.36 g, 0.71 mmol) was reacted with 1M BBr₃/CH₂Cl₂ (1.5 mL, 1.5 mmol) to give product 11 (0.29 g, 83%). ¹HNMR (CDCl₃) 0.85-0.90 (t, J=7.2 Hz, 3H, CH₃), 1.43-1.58 (m, 6H), 1.96-2.00 (m, 2H), 2.44-2.55 (m, 6H, CH₂NN(CH₂)₂), 2.69-2.77 (m, 8H), 2.94-2.95 (m, 1H), 3.08-3.09 (bs, 4H, N(CH₂)₂), 6.51-6.57 (m, 2H, Ar—H), 6.88-6.93 (m, 2H, Ar—H), 7.09-7.15 (m, 2H, Ar—H). Free base was converted into its HCl salt, m.p.=155-159° C. Anal. Calcd. (C₂₇H₃₇N₃OCl₂.3HCl 0.8H₂O)C, 52.79; H, 6.82; N, 6.84; Found: C, 52.50; H, 6.82; N, 6.84.

7-Hydroxyl-2-[N-propargyl-(N-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butyl)amino]tetralin 19b

Compound 18b (0.28 g, 0.70 mmol was reacted with 1M BBr₃/CH₂Cl₂ (1.50 mL, 1.50 mmol) to give pure product 8, 0.23 g (84%). ¹HNMR (CDCl₃) 1.48-1.56 (m, 4H), 2.09-2.13 (m, 2H), 2.17-2.18 (t, J=1.8 Hz, 1H, C≡CH), 2.45-2.47 (t, J=6.6 Hz, 2H), 2.66-2.68 (bs, 4H, N(CH₂)₂), 2.71-2.80 (m, 5H), 2.89-2.96 (m, 2H), 3.09-3.10 (bs, 4H, N(CH₂)₂), 3.51-3.52 (d, J=1.5 Hz, 2H, CH₂C≡CH), 6.57-6.61 (m, 2H, Ar—H), 6.92-6.98 (m, 2H, Ar—H), 7.14-7.16 (m, 2H, Ar—H). Free base was converted into its HCl salt, m.p.=180-183° C. Anal. Calcd. (C₂₇H₃₃N₃OCl₂.2.70HCl 0.06H₂O) C, 55.34; H, 6.16; N, 7.18; Found: C, 55.42; H, 6.16; N, 7.10.

4-[N-(4-phenylpiperazin-1-yl)-ethylamino]-cyclohexanone ethylene ketal 20

A mixture of amine 4a (2.21 g, 10.8 mmol), ketone (1.68 g, 10.8 mol) and Na(OAc)₃BH (3.24 g, 15.12 mmol) in HOAc(0.65 g, 10.8 mol) and ClCH₂CH₂Cl (40 mL) was stirred at room temperature for overnight. The reaction mixture was diluted with EtOAc(200 mL), washed with brine, and dried over Na₂SO₄. After the evaporation of the organic layer, the crude product was purified by flash chromatograpy(EtOAc/MeOH/Et₃N=100/5/1) to give white solid 20, 3.55 g (91%). ¹H NMR (300 MHz, CD₃Cl) 1.52-1.56(m, 6H), 1.74-1.79(m, 2H), 1.91-1.96(m, 2H), 2.57-2.66(m, 7H, N(CH₂)₂, CHNHCH₂), 2.80-2.84(t, J=6.0 Hz, 2H), 3.14-3.18(t, J=48 Hz, 4H, N(CH₂)₂), 3.90(s, 4H, OCH₂CH₂O), 6.83-6.91(m, 3H, Ar—H), 7.21-7.25(m, 2H, Ar—H).

4-[N-propyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]-cyclohexanone ethylene ketal 21

A mixture of amine 20 (1.0 g, 2.94 mmol), 1-bromopropane (1.45 g, 11.80 mol) and K₂CO₃ (1.22 g, 8.70 mmol) in dry DMF(20 mL) was stirred at 60° C. for 10 h. The mixture was poured into water(50 mL) and extracted with Et₂O (3×100mL). The combined organic layer was washed with brine and dried over Na₂SO₄. After the evaporation of the organic solvent, the residue was purified by flash chromatograpy(EtOAc/MeOH/Et₃N=100/2/1) to give a thick oil 21 0.80 g (70%). ¹H NMR(300 MHz, CD₃Cl) 0.83-0.88 (t, J=7.2 Hz, 3H, CH₃), 1.40-1.47(m, 2H), 1.52-1.58(m, 4H), 1.73-1.80(m, 4H), 2.41-2.50(m, 4H), 2.58-2.65(m, 7H), 3.17-3,20(t, J=5.2 Hz, 4H, N(CH₂)₂), 3.17-3.20(t, J=5.2 Hz, 4H, N(CH₂)₂), 3.92(s, 4H, OCH₂CH₂O), 6.82-6.86(t, J=7.2 Hz, 1H, Ar—H), 6.90-6.93(d, J=7.8 Hz, 2H, Ar—H), 7.22-7.28(m, 2H, Ar—H).

4-[N-propyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]-cyclohexanone 22

A solution of ketal 21 (2.00 g, 5.17 mmol) in THF (20 mL) and 1N HCl(20 mL) was stirred at 80° C. under N₂ for 2 h. THF was removed under vacuo and solid NaHCO₃ was added slowly extracted with EtOAc(3 x100 mL). The combined organic layer was washed with brine and dried over Na₂SO₄. The evaporation gave the crude product, which was purified by flash chromatograpy(EtOAc/Et₃N=100/1) to give 22, 1.31 g(99%). ¹H NMR (300 MHz, CD₃Cl) 0.87-0.90(t, J=5.7 Hz, 3H, CH₃), 1.43-1.51(dt, J=5.7, 6.0 Hz, 2H, NCH CH₂CH₃), 1.70-1.79(m, 2H), 2.04-2.07(m, 2H), 2.30-2.52(m, 8H), 2.64-2.70(m, 6H), 2.97-3.03(t, J=10.4 Hz, 1H, NCH(CH₂)), 3.19-3.21(t, J=4.4 Hz, 4H, N(CH₂)₂), 6.83-6.87(t, J=7.2 Hz, 1H, Ar—H), 6.91-6.93(d, J=8.0 Hz, 2H, Ar—H), 7.24-7.28(m, 2H, Ar—H).

2-Amino-6-[N-propyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]-5,6,7,8-tetrahydrobenzopyrimidine 23

To a solution of ketone 22 (0.60 g, 1.75 mmol) in dry toluene(20 mL) was added tris(dimethylamino)methane (1.27 g, 8.76 mmol), and the mixture stirred under nitrogen at 90° C. for 4 h. The solvent was removed under vacuo, and the residue was dissolved in EtOH (25 mL). Guandine carbonate (0.78 g, 4.33 mmol) was added, and the mixture was held at reflux for 17 h. The solvent was evaporated, and the residue diluted with CH₂Cl₂ and washed with brine. The organic layer was dried over Na₂SO₄ and evaporated to give the crude product, which was purified by flash chromatograpy (EtOAc/MeOH/Et₃N=25/1/1) to give a yellow solid 23, 0.61 g(88%). ¹H NMR(300 MHz, CD₃Cl) 0.86-0.91(t, J=7.2 Hz, 3H, CH₃), 1.44-1.52(dt, J=7.2, 7.2 Hz, 2H, NCH₂CH₂CH₃), 1.61-1.74(m, 1H), 2.03-2.10(m, 1H), 2.49-2.56(m, 4H), 2.64-2.67(t, J=5.0 Hz, 4H, N(CH₂)₂), 2.69-2.75(m, 4H), 2.79-2.81(dd, J=2.8, 6.0 Hz, 1H), 2.85-2.95(m, 1H), 3.18-3.21(t, J=5.0 Hz, 4H, N(CH₂)₂), 4.88(s, 2H, NH₂), 6.82-6.87(t, J=7.2 Hz, 1H, Ar—H), 6.90-6.93(d, J=8.4 Hz, 2H, Ar—H), 8.01(s, 1H, H-pyrimidine). Free base was converted into HCl salt. m.p.=97-102° C. Anal: (C₂₃H₃₄N₆.5HCl-0.2H₂O) Cacl: C, 47.90, H, 6.85, N, 14.47; Found: C, 48.36, H, 7.38, N, 14.48.

2-Bromo-4-[N-propyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]-cyclohexanone 24

Into the solution of ketone 22 (0.86, 2.51 mmol) in HOAc (50 mL) and 40% HBr/HOAc(w/v) (3.0 mL) was added Bromine (0.45 g, 2.81 mmol) in HOAc(10 mL) dropwise. The white solid was precipitated after several minutes. The mixture was stirred for 1 h and the most of solvent was removed under vacuo. The solid was collected with filtration and dried under vacuo to give 1.45 g(87%).

2-Amino-5-[N-propyl-(N-(4-phenylpiperazin-1-yl)-ethyl)amino]-4,5,6,7-tetrahydrobenzothiazole 25

A solution of bromide HBr salt 24 (0.99 g, 1.49 mmol), thiourea (0.14 g, 179 mmol) in EtOH (50 mL) was refluxed for 2 h. The solvent was removed under vacuo. The residue was diluted with EtOAc and solid NaHCO₃ was added. The mixture was filtered and the organic layer was evaporated to give crude product, which was purified with flash chromatography (EtOAc/Et₃N=100/1) to give pure compound 25, 140 mg. ¹H NMR(300 MHz, CD₃Cl)0.87-0.91(t, J=8.0 Hz, 3H, CH₃), 1.43-1.52(h, J=7.2 Hz, 2H, CH₃CH₂CH₂N), 1.69-1.79(dq, J=4.8, 12.8 Hz, 2H), 1.86(bs, 2H, NH2), 2.04-2.30(m, 2H), 2.30-2.38(dt, J=6.0, 13.6 Hz, 2H), 2.42-2.52(m, 6H), 2.64-7.71(m, 6H), 2.97-3.03(dt, J=3.4, 8.0 Hz, 1H), 3.19-3.21(t, J=5.2 Hz, 4H, N(CH₂)₂), 6.83-6.87(t, J=7.2 Hz, 1H, Ar—H), 6.91-6.93(d, J=8.0 Hz, 2H, Ar—H), 7.24-7.28(m, 2H, Ar—H).

2-(4-Nitro-phenyl)-N-[2-(4-phenyl-piperazin-1-yl)-ethyl]-acetamide (26a)

To a stirred solution of 2-(4-Phenyl-piperazin-1-yl)-ethylamine 4a (0.5 g, 2.44 mmol) and Et₃N (0.34 g, 3.41 mmol) in 40 mL of dry CH₂Cl₂ under nitrogen at 0° C. was added a solution (4-Nitro-phenyl)-acetyl chloride (0.58 g, 2.92 mmol). The temperature was allowed to rise to room temperature, the mixture was stirred for 2 h, and then washed with water. The aqueous layer was extracted with dichloromethane. The combined organic phase was washed with saturated sodium chloride, dried (Na₂SO₄) and concentrated. The crude product was purified by column chromatography over silica gel (EtOAc) to produce 26a: 0.8 g, (89% yield) as a white solid (mp: 138-139° C.). ¹H NMR (CDCl₃, 400 MHz): δ 2.52 (2H, t, J=5.6, CH₂—CH₂NH), 2.57 (4H, t, J=5.2, (CH₂)₂N—), 3.11 (4H, t, J=5.2, (CH₂)₂—NPh), 3.36-3.34 (2H, m, CH₂—NHCO), 3.65 (2H, s, CH₂Ar), 6.19 (1H, bs, NHCO), 6.86-6.91(3H, m, ArH), 7.25-7.29 (2H, m, ArH), 7.47 (2H, d, J=8.8, ArH), 8.16-8.19 (2H, m, ArH).

2-(3-nitro-phenyl)-N-[2-(4-phenyl-piperazin-1-yl)-ethyl]-acetamide (26b): (Procedure same as 26a)

2-(4-Phenyl-piperazin-1-yl)-ethylamine 4a (0.5 g, 2.43 mmol) was reacted with (3-Nitro-phenyl)-acetyl chloride (0.58 g, 2.92 mmol) in dichloro methane to give a crude product, which was purified by chromatography (EtOAc/Hexane=9/1) to produce 26b: 0.83 g (92% yield) as a yellow solid (mp: 115-116° C.). ¹H NMR (CDCl₃, 400 MHz): δ 2.51-2.57 (6H, m, (CH₂)₃N), 3.06-3.14 (4H, m, (CH₂)₂NPh), 3.36-3.39 (2H, m, CH₂—NHCO), 3.65 (2H, s, CH₂Ar), 6.16 (1H, bs, NHCO), 6.85-6.91(2H, m, ArH), 7.25-7.29 (3H, m, ArH), 7.50 (1H, t, J=8.4, ArH), 7.65 (1H, d, J=7.6, ArH). 8.11-8.15 (2H, m, ArH).

[2-(4-nitro-phenyl)-ethyl]-[2-(4-phenyl-piperazin-1-yl)-ethyl]-amine (27a):

To a stirred solution of NaBH₄ (0.449 g, 11.81 mmol) in 50 mL of dry THF at 0° C. under N₂ was added dropwise 48% w/w BF₃ ether complex (1.47 mL, 11.68 mmol). The cooling bath was removed and the solution was stirred for 1 h at room temperature. Into the above was added dropwise a solution of 2-(4-nitro-phenyl)-N-[2-(4-phenyl-piperazin-1-yl)-ethyl]-acetamide 26a (0.55 g, 1.49 mmol) dissolved in THF (5 mL). The reaction mixture was refluxed for 6 h. After the solution cooled to room temperature, methanol (5 mL) was added slowly. The solvent was removed under reduced pressure and 10% HCl/MeOH (25 mL) was added to the residue and the solution refluxed for 1 h. Solid NaHCO₃ was added and methanol was removed in vacuo. The mixture was extracted with EtOAc. The combined organic phase was dried over Na₂SO₄ and evaporated to give the crude product which was purified by chromatography (EtOAc/MeOH=4/1) to give 27a: 0.385 g (73% yield) as a colorless oil. ¹H NMR (CDCl₃, 400 MHz): δ 1.62 (1H, bs, NH), 2.50 (2H, t, J=5.6 Hz, CH₂—CH₂NH), 2.58 (4H, t, J=4.8 Hz, (CH₂)₂N), 2.76 (2H, t, J=5.6 Hz, CH₂Ar), 2.90-2.96 (4H, m, (CH₂)₂NH), 3.14 (4H, t, J=4.8 Hz, (CH₂)₂NPh), 6.85 (1H, t, J=7.2, ArH), 6.90 (2H, d, J=9.2, ArH), 7.25 (2H, t, J=9.2, ArH), 7.37 (2H, d, J=8.8, ArH), 8.15 (2H, d, J=8, ArH).

[2-(4-nitro-phenyl)-ethyl]-[2-(4-phenyl-piperazin-1-yl)-ethyl]-amine (27b): (Procedure same as 27a)

2-(3-nitro-phenyl)-N-[2-(4-phenyl-piperazin-1-yl)-ethyl]-acetamide 26b (0.53 g, 1.43 mmol) was reacted with the stirred solution of NaBH₄ (0.433 g, 11.39 mmol) and 48% w/w BF₃ ether complex (1.42 ml, 11.28 mmol) in dry THF to produce a crude product, which was purified by chromatography (EtOAc)/MeOH=4/1) to give 27b: 0.375 g (74% yield) as a colorless oil. ¹H NMR (CDCl₃, 400 MHz): δ 1.62 (1H, bs, NH), 2.52-2.59 (6H, m, (CH₂)₂N), 2.77 (2H, t, J=5.6, CH₂Ar), 2.90-2.98 (4H, m, (CH₂)₂NH), 3.13 (4H, t, J=5.6, (CH₂)₂NPh), 6.85 (1H, t, J=7.2, ArH), 6.90 (2H, d, J=8.4 Hz, ArH), 7.2 (2H, t, J=9.2, ArH), 7.45 (1H, t, J=8 Hz, ArH), 7.55 (1H, d, J=7.2 Hz, ArH), 8.05 (1H, d, J=8 Hz, ArH), 8.09 (1H, s, ArH).

N-[2-(4-Nitro-phenyl)-ethyl]-N-[2-(4-phenyl-piperazin-1-yl)-ethyl]-propionamide (28a):

To a stirred solution of [2-(4-nitro-phenyl)-ethyl]-[2-(4-phenyl-piperazin-1-yl)-ethyl]-amine 27a (0.375 g, 1.05 mmol), Et₃N (0.267 g, 2.64 mmol) in 25 mL of dry CH₂Cl₂ under nitrogen at 0° C. was added a solution of propionyl chloride (0.137 g, 1.48 mmol). The temperature was allowed to rise to room temperature, the mixture stirred for 2 h, and then washed with water. The aqueous layer was extracted with dichloromethane. The combined organic phase was dried (Na₂SO₄) and concentrated. The crude product was purified by column chromatography over silica gel (EtOAc/Hex=9/1) to give 28a as a colorless oil: 0.39 g (89% yield). ¹H NMR (CDCl₃, 400 MHz): δ 1.16 (3H, t, J=7.2, CH₃), 2.38 (2H, q, J=7.2, CH₂), 2.51 (2H, t, J=7.2 Hz, CH₂Ar), 2.62 (4H, t, J=4.8, (CH₂)₂N), 2.99 (2H, t, J=7.2, CH₂—CH₂NCO), 3.15-3.20 (4H, m, (CH₂)₂NHPh, 3.32 (2H, t, J=7.2, CH₂—CH₂Ar), 3.58 (2H, t, J=7.2, CH₂NCO), 6.83-6.93 (3H, m, ArH), 7.23-7.28 (2H, m, ArH), 7.34 (1H, d, J=8.0, ArH), 7.38 (1H, d, J=8.8, ArH, 8.15 (1H, d, J=8.8, ArH), 8.18 (1H, d, J=8.4, ArH).

N-[2-(3-nitro-phenyl)-ethyl]-N-[2-(4-phenyl-piperazin-1-yl)-ethyl]-propionamide (28b): (Procedure same as 28a)

[2-(4-nitro-phenyl)-ethyl]-[2-(4-phenyl-piperazin-1-yl)-ethyl]-amine 27b (0.375 g, 1.05 mmol) was reacted with propionyl chloride (0.137 g, 1.48 mmol) in presence of Et₃N (0.267 g, 2.64 mmol) in dry CH₂Cl₂ to produce a crude product, which was purified by chromatography (EtOAc/Hex=9/1) to give 28b: 0.398 g (92% yield) as a colorless oil. ¹H NMR (CDCl₃, 400 MHz): δ 1.16 (3H, t, J=7.2 Hz, CH₃), 2.38 (2H, q, J=7.2 Hz, CH₂), 2.52 (2H, t, J=7.2 Hz, CH₂Ar), 2.62 (4H, t, J=4.8 Hz, (CH₂)₂N), 2.99 (2H, t, J=7.2 Hz, CH₂—CH₂NCO), 3.16-3.21 (4H, m, (CH₂)₂NHPh, 3.34 (2H, t, J=7.2 Hz, CH₂—CH₂Ar), 3.59 (2H, t, J=7.2 Hz, CH₂NCO), 6.83-6.88 (1H, m, ArH), 6.91 (2H, d, J=8 Hz, ArH), 7.23-7.30 (2H, m, ArH), 7.44-7.60 (2H, m ArH), 8.07-8.13 (2H, m, ArH).

4-(2-{[2-(4-Phenyl-piperazin-1-yl)-ethyl]-propyl-amino}-ethyl)-phenylamine (29a):

N-[2-(4-nitro-phenyl)-ethyl]-N-[2-(4-phenyl-piperazin-1-yl)-ethyl]-propionamide 28a (0.33 g, 0.80 mmol) was dissolved in dry EtOH (20 mL) and 10 wt % Pd/C (0.05 g) was added. The mixture was stirred for overnight under H₂ at 1 atm. Pressure. The reaction mixture was filtered through celite and filtrate was concentrated under reduced pressure and kept under vacuum for 1 h to give the corresponding aniline. In to the solution of the crude product in 15 ml dry THF was added 1(M) BH₃/THF (7 mL, 7 mmol). The reaction mixture was refluxed for 6 h. After the solution was cooled to room temperature, methanol (5 mL) was added slowly. The solvent was removed under reduced pressure and 10% HCl/MeOH (25 mL) was added into the residue and the solution was refluxed for 1 h. Solid NaHCO₃ was added and the methanol was removed in vacuo. The mixture was extracted with EtOAc. The combined organic phase was dried over Na₂SO₄ and evaporated to give the crude product which was purified by chromatography (EtOAc/MeOH=9/1) to give 29a as a colorless oil: 0.23 g (78% yield). ¹H NMR (CDCl₃, 300 MHz): δ 0.89 (3H, t, J=7.2 Hz, CH₃), 1.50 (2H, q, J=7.2 Hz, CH₂), 2.48-2.57 (4H, m, CH₂Ar, (CH₂)N), 2.63-2.75 (10H, m, (CH₂)₃N, (CH₂)₂N), 3.20 (4H, t, J=4.8 Hz, (CH₂)₂NPh), 3.56 (2H, bs, NH₂), 6.62 (2H, d, J=8.7 Hz, ArH), 6.85 (1H, t, J=9.6 Hz, ArH), 6.91-6.99 (4H, m, ArH), 7.25 (2H, t, J=9 Hz, ArH). Free base was converted into its hydrochloride salt, mp 262-264° C. Elemental analysis calculated for C₂₃H₃₈N₄Cl₄,1.05H₂O:C, 51.99; H, 7.60; N, 10.54. Found C, 52.37; H, 7.89; N, 10.12.

3-(2-{[2-(4-Phenyl-piperazin-1-yl)-ethyl]-propyl-amino}-ethyl)-phenylamine (29b): (Procedure same as 29a)

N-[2-(3-nitro-phenyl)-ethyl]-N-[2-(4-phenyl-piperazin-1-yl)-ethyl]-propionamide 28b (0.33 g, 0.80 mmol) was reacted with H₂ in presence of 10 wt % Pd/C (0.05 g) to produce corresponding aniline, which was then reacted with 1(M) BH₃/THF (7 ml, 7 mmol) to produce a crude product. The crude product was purified by chromatography (EtOAc/MeOH=9/1) to give 29b as a colorless oil 0.248 g (81% yield). ¹H NMR (CDCl₃, 400 MHz): δ 0.89 (3H, t, J=7.2 Hz, CH₃), 1.50 (2H, q, J=7.2 Hz, CH₂), 2.48-2.56 (4H, m, CH₂Ar, (CH₂)N), 2.61-2.74 (10H, m, (CH₂)₃N, (CH₂)₂N), 3.20 (4H, t, J=4.8 Hz, (CH₂)₂NPh), 3.60 (2H, bs, NH₂), 6.51-6.54 (2H, m, ArH), 6.57-6.61 (1H, m, ArH), 6.85 (1H, t, J=7.2 Hz, ArH), 6.92 (2H, d, J=8.8 Hz, ArH), 7.04-7.08 (1H, m, ArH), 7.24-7.28 (2H, m, ArH). Free base was converted into its hydrochloride salt, mp 278-284° C. Elemental analysis calculated for C₂₃H₃₈N₄Cl₄,0.0475H₂O:C, 53.03; H, 7.54; N, 10.75. Found C, 53.39; H, 7.96; N, 10.26.

4-Chloro-N-[4-(2-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino}-ethyl)-phenyl]-benzenesulfonamide (30a):

To a stirred solution of 6a (0.04 g, 0.01 mmol) and Et₃N (0.033 g, 0.32 mmol) in dry DMF (5 ml) under nitrogen gas was added 4-Chloro-benzenesulfonyl chloride and allowed to stir overnight. Water was added to the reaction mixture and extracted thrice with diethyl ether. The combined organic phase was washed with saturated sodium chloride, dried (Na₂SO₄) and concentrated. The crude product was purified by chromatography (EtOAc/MeOH=4/1) to produce 30a: 0.042 (75% yield) as a colorless oil. ¹H NMR (CDCl₃, 300 MHz): δ 0.85 (3H, t, J=7.2 Hz, CH₃), 1.45 (2H, q, J=7.2 Hz, CH₂), 2.43-2.51 (4H, m, CH₂Ar, (CH₂)N), 2.61-2.69 (10H, m, (CH₂)₃N, (CH₂)₂N), 3.19 (4H, t, J=4.8 Hz, (CH₂)₂NPh), 6.85 (1H, t, J=7.2 Hz, ArH), 6.91-6.96 (3H, m, ArH), 7.08 (3H, d, J=8.4 Hz, ArH), 7.23-7.29 (2H, m, ArH), 7.38 (2H, d, J=8.4 Hz, ArH), 7.62-7.66 (2H, d, J=8.7 Hz, ArH). Free base was converted into its hydrochloride salt, mp 224-226° C. Elemental analysis calculated for C₂₉H₄₀Cl₄N₄O₂S, 0.25H₂O: C, 53.17; H, 6.23; N, 8.55. Found C, 53.19; H, 6.43; N, 8.15.

4-Chloro-N-[3-(2-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino}-ethyl)-phenyl]-benzenesulfonamide (30b): (Procedure same as 30a)

29b (0.05 g, 0.136 mmol), Et₃N (0.05 mL, 0.341 mmol) and 4-Chloro-benzenesulfonyl chloride (0.043 g, 0.2046 mmol) were reacted (procedure same as for 7a) to afford the title product 30b (0.058 g, 78%) as a colorless oil. ¹H NMR (CDCl₃, 300 MHz): δ 0.88 (3H, t, J=7.3 Hz, CH₃), 1.45 (2H, q, J=7.1 Hz, CH₂), 1.7 (1H, bs, NH), 2.45-2.55 (4H, m, CH₂Ar, (CH₂)N), 2.62-2.71 (10H, m, (CH₂)₃N, (CH₂)₂N), 3.21 (4H, t, J=4.8 Hz, (CH₂)₂NPh), 6.86 (1H, t, J=7.2, ArH), 6.91-6.95 (3H, m, ArH), 7.00 (2H, d, J=7.8, ArH), 7.14-7.19 (3H, m, ArH), 7.39 (2H, d, J=8.7 Hz, ArH), 7.67 (2H, d, J=8.7 Hz, ArH). The free base was converted into its hydrochloride salt, mp 220-224° C. Elemental analysis calculated for C₂₉H₄₀Cl₄N₄O₂S,1.5H₂O: C=51.41; H=6.39; N=8.27. Found C=51.13; H=6.24; N=7.78.

Appendix REFERENCES

-   1. Civelli, O., Bunzow, J. R., Grandy, D. K., Molecular Diversity of     the Dopamine Receptors. ANNU. REV. PHARMACOL. TOXICOL, 32, 281-307,     1993. -   2. Seeman, P., Tol Van, H., Dopamine Receptor Pharmacology. TIPS,     15, 264-270, 1994. -   3. Kebabian, J. W., Calne, D. N., Multiple Receptors for Dopamine.     NATURE, 277, 93-96, 1979. -   4. Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L.,     Schwartz, J.-C, Molecular Cloning and Characterization of a Novel     Dopamine Receptor (D3) as a Target for Neuroleptics. NATURE, 347,     146, 1990. -   5. Giros, B., Matres, M. P., Sokoloff, P., Scwartz, J. C. R. ACAD.     SCI. [III], 1990, 311, 501. -   6. Sokoloff, P. et. al., Dopamine Receptors and Transporter     Pharmacology, Structure and Function (Niznik, H. B., ed), pp 165-,     Marcel Dekker. -   7. Livingstone, C. D., Strange, P. G., Naylor, L. H., Molecular     Modeling of D2-like Dopamine Receptors. BIOCHEM. J. 287, 277-282,     1992. -   8. Seeman, P., SYNAPSE, 1, 133-152, 1987. -   9. Jenner, P., Marsden, C. D., Drugs in Central Nervous System     Disorders, Horwell, D. C., Ed., Marcel Dekker: New York 1985,     149-262. -   10. Landwehr, B., Mengod, G., Palacios, J. M., MOL. BRAIN. RES., 18,     187-, 1993. -   11. Sokoloff, P., Martres, M-P., Giros, B., Bouthenet, M-L.,     Schwartz, J-C., BIOCHEM. PHARMACOL. 43, 659-, 1992. -   12. Schwartz, J-C., Levesque, D., Martes, M-P., Sokoloff, P., CLIN.     NEUROPHARMACOL. 16, 295-, 1993. -   13. Levant, B., The D3 Dopamine Receptor: Neurobiology and Potential     Clinical Relevance, PHARMACOL. REV., 49, 231-252, 1997. -   14. Caine, S. B., Koob, G. F., Modulation of Cocaine     Self-administration in the Rat Through D-3 Dopamine Receptors,     SCIENCE, 260, 1814-1816, 1993. -   15. Caine, S. B., Koob, G. F., Pretreatment with the Dopamine     Agonist 7-oh-dpat Shifts the Cocaine Self-Administration Dose Effect     Function to the Left under Different Schedules in the Rat, BEHAV.     PHARMACOL., 6, 333-347, 1995. -   16. Pilla, M., Perachon, S., Sautel, F., Garrido, F., Mann, A.,     Wermuth, C., Schwartz, J-C., Everitt, B. J., Sokoloff, P., Selective     Inhibition of Cocaine-seeking Behaviour by a Partial Dopamine D3     Receptor Agonist. NATURE, 400, 371-375, 1999. -   17. Canon, J. G., Lee, T., Goldman, H. D., Costall, B., Naylor, R.     J., Cerebral Dopamine Agonist Properties of Some 2-aminotetralin     Derivatives after Peripheral and Intracerebral Administration, J.     MED. CHEM., 20, 1111-1116, 1977. -   18. McDermed, J., McKenzie, G., Phillips, A., Synthesis and     Pharmacology of Some 2-aminotetralins. Dopamine Receptor     Agonists, J. MED. CHEM. 18, 362-367, 1975. -   19. McDermed, J. D., McKenzie, G. M., Freeman, H. S., Synthesis and     Dopaminergic Activity of (±)—, (+)-, and     (−)-2-dipropylamino-5-hydroxy-1,2,3,4-tetrahydronapthalene, J. MED.     CHEM. 19, 547-549, 1976. -   20. Hacksell, U., Svensson, U., Nilsson, J. L. G., Hjorth, S.,     Carlsson, A., Wikstrom, H., Lindberg, Sanchez, D., N-Alkylated     2-aminotetralins: Central Dopamine-receptor Stimulating Activity, J.     MED. CHEM. 22, 1469-1475, 1979. -   21. Levesque, D., Diaz, J., Pilon, C., Martres, M.-P., Giros, B.,     Souil, E., Schott, D., Morgat, J.-L., Schwartz, J.-C., Sokoloff, P.,     Identification, Characterization, and Localization of the Dopamine     D₃ Receptor in Rat Brain Using     7-[³H]hydroxy-N,N-di-n-propyl-2-aminotetralin. PROC. NATL. ACAD.     SCI. U.S.A., 89, 8155-8159, 1992. -   22. Alexander van Vliet, L., Tepper, P. G., Dijkstra, D., Damsma,     G., Wikstrom, H., Pugsly, T. A., Akunne, H. C., Heffner, T. G.,     Glase, S. A., Wise, L. D., Affinity for Dopamine D₂, D₃ and D₄     Receptors of 2-aminotetralins. Relevance of D₂ Agonist Binding for     Determination of Receptor Subtype Selectivity, J. MED. CHEM. 39,     4233-4237, 1996. -   23. John Murray, P., Harrison, L. A., Johnson, M. R., Robertson, G.     M., Scopes, D. I., Bull, D. R., Graham, E. A., Hayes, A. G.,     Kilpatrick, G. J., Dass, I. D., Large, C., Sheehan, M. J.,     Stubbs, C. M., Turpin, M. P., A Novel Series of Arylpiperazines with     High Affinity and Selectivity for the Dopamine D₃ Receptor, BIOORG.     MED. CHEM. LETT., 5, 219-222, 1995. -   24. Teran, C., Santana, L., Uriarte, E., Fall, Y., Unelius, L.,     Tolf, B-R, Phenylpiperazine Derivatives with Strong Affinity for     5HT1a, D2A and D3 Receptors, BIOORG. MED. CHEM. LETT., 8, 3567-3570,     1998. -   25. Boyfield, I., Coldwell, M. C., Hadley, M. S., Johnson, C. N.,     Riley, G. J., Scott, E. E., Stacey, R., Stemp, G., Thewlis, K. M., A     Novel Series of 2-aminotetralins with High Affinity and Selectivity     for the Dopamine D₃ Receptor. BIOORG. MED. CHEM. LETT., 7,     1995-1998, 1997. -   26. Yuan, J., Chen, X., Brodbeck, R., Primus, R., Braun, J.,     Wasley, J. F., Thurkauf, A., NGB 2904 and NGB 2849: Two Highly     Selective Dopamine D₃ Receptor Antagonist. BIOORG. MED. CHEM. LETT.,     8, 2715-2718, 1998. -   27. Homan, E. J., Copinga, S., Elfstrom, L., Veen, T., Hallema,     J-P., Mohell, N., Unelius, L., Johansson, R., Wikstrom, H. V.,     Grol, C. J., 2-aminotetralin-derived Substituted Benzamide with     Mixed Dopamine D₂, D₃, and Serotonin 5-HT1A Receptor Binding     Properties: A Novel Class of Potential Atypical Antipsychotic     Agents, BIOORG. MED. CHEM. 6, 2111-2126, 1998. -   28. Avenell, K. Y., Boyfield, I., Hadley, M. S., Johnson, C. N.,     Nash, D. J., Riley, G. J., Stemp, G., Heterocyclic Analogues of     2-aminotetralins with High Affinity and Selectivity for the Dopamine     D₃ Receptor, BIOORG. MED. CHEM. LETT. 9, 2715-2720, 1999. -   29. Pugsley, T. A., Davis, H. C. Akunne, H. C., Mackenzie, R. G.,     Shih, Y. H., Damsma, G., Wikstrom, H., Whetzel, S. Z., Georgic, L.     M., Cooke, L. W., Demattos, S. B., Corbin, A. E. Glase, S. A.,     Wise, L. D., Dijkstra, D., Heffner, T. G., J. PHARMACOL. EXP. THER.,     275, 1355-1366, 1995. -   30. Pilon, C., Levesque, D., Dimitriadou, V., Griffon, N.,     Martres, M. P., Schwartz, J. C., and Sokoloff, P., EUR. J.     PHARMACOL., 268: 129-139, 1994. -   31. Millan, M. J. et al., J. PHARMACOL. EXP. THER., 286, 1341-1355,     1998. -   32. Ravina, E. et al., J. MED. CHEM., 43, 4678-4693, 2000. -   33. Watts, V. J., Lawler, C. P., Knoerzer, T., Mayleben, M. A.,     Neve, K. A., Nichols, D. E., Mailman, R. B., EUR. J. PHARMACOL.,     239, 271-273, 1993. -   34. Dutta, A. K., Fei, X.-S., Reith, M. E. A., BIORG. MED. CHEM.     LETT., 12:4:619-6, 2002. -   35. Kula, N. S. et al., CELL. MOL. NEUROBIOL., 14, 185-191, 1994. 

1. A compound exhibiting CNS activity in mammalian species, having the structure (I)

wherein A is an optionally heterocyclic aromatic ring system containing from 1 to 4 aromatic or heteroaromatic rings, optionally fused;

comprises an aromatic ring system wherein X and Y are moieties which complete a 5 or 6 membered aromatic ring optionally containing N, O, S, or Se heteroatoms; R² is a C₁₋₁₀ hydrocarbon group substituent or two R² together may form a fused ring system, said hydrocarbon group and said fused ring system optionally containing one or more O, N, S, or Se heteroatoms, or R² is a hydroxyl or amino group, o is an integer from 0 to 4, the upper limit of o bounded by the number of available substitutent sites on said optionally heterocyclic 5 or 6 membered aromatic ring structure; n is an integer from 0 to 2; R¹ is an organyl group selected from the group consisting of C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl, C₆₋₁₀ aryl, each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, etc. groups optionally halo substituted and/or substituted by —CN, Cl₄ lower alkoxy, C₁₋₄ acyloxy, C₁₋₄ acyl, or —C(O)—R⁴; —R⁵—NH—SO₂—NR⁴ _(r) where R⁵ is C₁₋₈ alkylene and r is 2 or 3, with the proviso that when r is 3, the nitrogen of the NR⁴ _(r) group will bear a positive formal charge; —R⁵—NH—C(O)—R⁴; —R⁵—NR⁴ _(r), —R⁵—Ar where Ar is an aryl ring system, optionally including one or more O, N, S, or Se heteroatoms and wherein R¹, together with (CH₂)_(p) may form an alicyclic sic membered ring, and wherein R¹, together with the six membered alicyclic ring of structure (I) may form a fused six membered alicyclic ring; p is 1 to 4; wherein one (CH₂)_(n) group may be replaced by O, or S, or Se; or a pharmaceutically acceptable derivative thereof.
 2. The compound of claim 1 wherein: R² is selected from the group consisting of C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl; C₆₋₁₀ aryl, —NR⁴ _(q) where R⁴ individually are H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl, C₆₋₁₀ aryl and q is 3 or 4, with the proviso that when q is 4, the group bears a positive formal charge; —NR⁴—C(O)—R⁴, —NR⁴—C(O)—NR⁴ ₂ wherein the above hydrocarbon groups may optionally be substituted with —CN, C, ₄ lower alkyl, —OR⁴, —OH, and halo; and A is an optionally heterocyclic aromatic ring system containing 1 to 4 optionally fused aromatic five or six membered rings, one or more rings optionally substituted by one or more C₁₋₄ alkyl, C₂₋₄ alkenyl, C₅₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, halo, C₁₋₄ aldehydo, or —NR⁴ _(q) groups.
 3. The compound of claim 1 wherein A is selected form the group consisting of phenyl, 2-methoxyphenyl, 2,3-dichlorophenyl, 4-(methylsulfonamino)phenyl, and biphenyl.
 4. A compound of claim 1, selected from the group consisting of:

wherein each Z independently is O, N, S, Se, or a CH or CH₂ group.
 5. The compound of claim 1, wherein said derivative is a salt, ester, amide, urea, or carbamide.
 6. The compound of claim 2, wherein said derivative is a salt, ester, amide, urea, or carbamide.
 7. A method of altering the CNS activity of a mammalian species, comprising administering a CNS activity affecting amount of at least one compound of claim
 1. 8. A method of altering the CNS activity of a mammalian species, comprising administering a CNS activity affecting amount of at least one compound of claim
 2. 9. A method of altering the CNS activity of a mammalian species, comprising administering a CNS activity affecting amount of at least one compound of claim
 3. 10. A method of altering the CNS activity of a mammalian species, comprising administering a CNS activity affecting amount of at least one compound of claim
 4. 11. The method of claim 7, wherein said compound has a greater affinity for a D3 receptor subtype than a D2 receptor subtype.
 12. The method of claim 7, wherein said mammalian species exhibits the symptoms of Parkinson's disease and said altering of CNS activity results in decreasing said symptoms.
 13. The method of claim 7, wherein said mammalian species exhibits cocaine addition, and said altering of CNS activity results in reducing a craving for cocaine.
 14. The method of claim 7, wherein said compound comprises

wherein R¹ is 3-propargyl or n-propyl, or a pharmaceutically acceptable derivative thereof.
 15. The method of claim 7, wherein said compound comprises

wherein R¹ is propyl, or a pharmaceutically acceptable derivative thereof.
 16. The method of claim 7, wherein said compound comprises

wherein R¹ is propyl, or a pharmaceutically acceptable derivative thereof.
 17. The method of claim 7, wherein said mammalian species exhibits symptoms of depression, and said compound reduces said symptoms.
 18. The method of claim 7, wherein said mammalian species exhibits symptoms of schizophrenia and said compound reduces said symptoms. 